

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
15 September 2005 (15.09.2005)

PCT

(10) International Publication Number
WO 2005/085867 A2

(51) International Patent Classification⁷: **G01N 33/68**

(21) International Application Number:
PCT/IB2005/000382

(22) International Filing Date: 14 February 2005 (14.02.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/548,719 27 February 2004 (27.02.2004) US

(71) Applicant (for JP only): **PFIZER JAPAN, INC.** [JP/JP];
Shinjuku Bunka Quint Bldg., 3-22-7, Yoyogi, Shibuya-ku,
Tokyo 151-8589 (JP).

Yasuhito [JP/JP]; Pfizer Global Research and Develop-
ment, 2, Aza 5-gochi, Taketoyo-cho, Chita-gun, Aichi-ken
470-2393 (JP). **KACHI, Hiroko** [JP/JP]; Pfizer Global
Research and Development, 2, Aza 5-gochi, Taketoyo-cho,
Chita-gun, Aichi-ken 470-2393 (JP). **TOMOTOSHI,**
Kimihiko [JP/JP]; Pfizer Global Research and Develop-
ment, 2, Aza 5-gochi, Taketoyo-cho, Chita-gun, Aichi-ken
470-2393 (JP). **SHINJO, Katsuhiko** [JP/JP]; Pfizer Global
Research and Development, 2, Aza 5-gochi, Taketoyo-cho,
Chita-gun, Aichi-ken 479-2393 (JP). **KOMADA, Tohru**
[JP/JP]; Pfizer Global Research and Development, 2, Aza
5-gochi, Taketoyo-cho, Chita-gun, Aichi-ken 470-2393
(JP).

(74) Agents: **FULLER, F., Grover, Jr.** et al.; Pfizer Inc., 201
Tabor Road, Morris Plains, NJ 07950 (US).

(71) Applicant (for all designated States except JP, US):
PFIZER INC. [US/US]; 235 East 42nd Street, New York,
NY 10017 (US).


(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,

(72) Inventors; and

(75) Inventors/Applicants (for US only): **TANIGUCHI,**

[Continued on next page]

(54) Title: GPR35



(57) Abstract: The present invention primarily relates to function analysis of GPR35, an orphan GPCR (G protein coupled receptor), a screening method to identify modulators (agonists/antagonists) of the receptor, cells stably expressing the receptor, and the discovery of modulators of the receptor. The present invention also relates to novel rat GPR35.



MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

GPR35

Technical Field of the Invention

The present invention primarily relates to function analysis of GPR35, an orphan
5 GPCR (G protein coupled receptor), a screening method to identify modulators
(agonists/antagonists) of the receptor, cells stably expressing the receptor, and the discovery
of modulators of the receptor. The present invention also relates to novel rat GPR35.

Background Art of the Invention

10 G protein coupled receptors are a large superfamily of integral membrane
proteins, involved in a broad range of signaling pathways. Most G protein-coupled receptors
are characterised by 7 transmembrane-spanning helices, and are therefore also called 7-
transmembrane receptors (7TMs). There are at least several hundred members of this
family, which include receptors responding to a wide range of different stimuli, including
15 peptides, biogenic amines, lipids, neurotransmitters, hormones, nucleotides,
sugar-nucleotides, cytokines, etc. Structurally, the receptors of this family consist of an
extracellular amino terminal domain, seven membrane-spanning hydrophobic regions, six
loop regions, three of which are extracellular, the other three being intracellular, and an
intracellular carboxy terminal domain. The hydrophobic regions show considerable
20 homology between the different members of this family, whereas the loop regions, as well as
the amino and carboxy terminal domains, are quite diverse, showing high homology only
amongst closely related receptor subtypes.

G proteins are heterotrimeric complexes, containing an α , a β , a γ -subunits in
which α is bigger than β and β is bigger than γ . At least 20 human genes are known to
25 encode the GTP-binding α -subunits. Furthermore, there are at least 5 genes encoding the β -
subunits and at least 11 genes encoding γ -subunits.

The α -subunit family is divided into four subfamilies on the basis of their
homology:

(1) The G_s family is typically able to stimulate adenylyate cyclase upon agonist binding to the
30 receptor coupling to it, and therefore lead to an increase in intracellular cyclic AMP.

(2) The Gq family, which includes Gq α , G11 α , G14 α , G16 α , lead to activation of phospholipase C.

(3) G12 and G13 appear to regulate classes of small molecular weight G proteins and Na⁺-H⁺ exchange.

- 5 (4) The Gi family typically mediate inhibition of adenylyate cyclase. More than half of the α -subunits are members of the Gi family and include the ubiquitously expressed and nearly identical Gi1 α , Gi2 α and Gi3 α , as well as several with a limited expression, such as Gz α , Go α and transducin.

Initiation of signal transduction cascades involving G proteins requires the
10 binding of a ligand to a G protein-coupled receptor (GPCR). This results in the stabilisation of conformations of the GPCR that increases the rate of dissociation of the bound GDP from the nucleotide binding pocket of G α subunit of a G protein. Binding of GTP is thus allowed. With GTP bound, the G protein dissociates into GTP-G α and G $\beta\gamma$ moieties and can hence regulate directly or otherwise the activity of several enzymes, which generate intracellular
15 signalling molecules (e.g. cyclic AMP), or the probability of opening a range of ion channels (Gilman, A.G. (1987) Annu Rev. Biochem. 56, 614-649). Following G protein activation, hydrolysis of bound GTP by intrinsic GTPase activity terminates its ability to regulate its effectors and leads to α -GDP reassociation with $\beta\gamma$. The G protein therefore serves a dual role, as a relay transmitting the signal from the receptor to the effector, and as a clock that
20 controls the duration of the signal. Therefore, depending on which GPCR couples to which G protein, very different intracellular effects can result, e.g. stimulation or inhibition of adenylyate cyclase, leading to increased or decreased cyclic AMP concentrations in the cells, opening of ion channels, etc.

GPCRs are very important targets for pharmaceutical intervention. Many
25 agonists and antagonists of the GPCRs of known functions are important for the treatment of diseases. Examples include but are not limited to, β 1-adrenergic receptor antagonists used for treating hypertension, angina and heart failure, dopamine D2 antagonists used for the treatment of schizophrenia, and β 2-adrenergic receptor agonists used for the treatment of asthma. Over the past 15 years, nearly 350 therapeutic agents targeting GPCRs have
30 been introduced onto the market, and it is estimated that around 30% of clinically prescribed

drugs function as either agonists or antagonists at GPCRs.

Therefore, it is likely that amongst the orphan receptors, there are further therapeutic targets which can play a key role in treating or preventing diseases or dysfunctions, including, but not limited to, pain, cancers, obesity, eating disorders, hypertension, hypotension, heart failure, incontinence, asthma, chronic bronchitis, angina, ulcers, psychotic and neurological disorders, viral infections including HIV-1 or HIV-2, other infections, inflammatory conditions, sexual dysfunction, urogenital disorders, and many other disorders, diseases or dysfunctions. It is therefore clearly highly desirable to find the physiological function for each GPCR.

However, it is not at all easy to find the physiological function for each GPCR as discussed below.

The conserved structure and hydrophobicity profile of this receptor family has allowed the identification and cloning of some members of this family, both through cloning experiments, e.g. degenerate polymerase chain reaction or cDNA library screening with probes derived from GPCR sequences using low stringency, and through bioinformatic mining of sequence databases. For many of these receptors, it is yet unclear what their functions are. These receptors are referred to as "orphan receptors". Through detailed analysis of their sequences and comparison with the sequences of GPCRs with known ligands, hypotheses can be generated as to the class of ligands that the orphan receptor may respond to.

However, these predictions are often tenuous, and it is still difficult to identify the ligand that such an orphan receptor may respond to. This is mainly because stimulation of GPCRs can lead to a multitude of different intracellular effects, which are mediated through the coupling to different G proteins. The G proteins in turn act on a whole range of signalling proteins, including phospholipase C, adenylate cyclase and ion channels, and thereby initiate a cascade of events in the cells.

It is difficult to predict from the sequence of the GPCR which G protein it will couple to, and in some cases the resulting intracellular effects are difficult to measure. Furthermore, the usual host cells used for heterologous expression of cloned GPCRs only express certain G proteins. Therefore, if the G protein that the orphan GPCR couples to is not expressed in these cells, the binding of an agonist to this receptor will not have a

measurable effect, making it unlikely that one could find the agonist(s) for the GPCR in such a system. It is therefore necessary to engineer specialized host cell lines, expressing various heterologous G proteins, to enable the establishment of host cell systems that can lead to measurable responses for many of the different GPCRs.

5 With regard to GPR35, there are several articles that report nucleotide and/or amino acid sequence of human and/or mouse GPR35. However, none of them reveals specific physiological function of GPR35. All that has been previously disclosed merely presumes that GPR35 is a GPCR.

 “Discovery of three novel G-protein-coupled receptor genes (O’Dowd BF et al. Genomics 47 (2), 310-313 (1998))” discloses cDNA and amino acid sequences of human GPR35. However, this report merely assumes the GPR35 is a GPCR. Needless to say, it does not mention any physiological function of the GPR35. Northern blotting was employed to determine tissue distribution. However, in rats, GPR35 expression was detected in the intestine but not in the heart, spleen, liver, lung, ovary, kidney, nor whole brain. In humans, 15 the expression was not detected in the caudate-putamen, thalamus, frontal cortex, midbrain, lung, nor adrenal. The expression in the DRG, dorsal horn, or spinal cord which is closely related to a neural activity, was therefore not detected.

 “Genetic variation in the gene encoding calpain 10 is associated with type 2 diabetes mellitus (Horikawa Y et al. Nat. Genet. 26:163-175 (2000))” discloses the cloning of mouse GPR35 gene. In this article, however, genes and SNPs located in the NIDDM1 region on chromosome 2 (which is suspected of relating to NIDDM), were examined at random to verify the linkage (association) between the disease and SNPs, in order to identify genetic elements related to non-insulin dependent diabetes mellitus (NIDDM) also known as type 2 diabetes. Although this article provides the findings that the GPR35 gene is located 25 in the NIDDM1 region and that there are a number of polymorphisms of human GPR35, it did not mention specific physiological functions of GPR35 nor lead to a positive conclusion concerning its relationship with NIDDM.

 Since the sequences of human GPR35 and mouse GPR35 are known, some biotechnology companies may prepare antibodies or knockout animals according to the 30 consignment and, in general, the nondisclosure agreement. These can be employed only as

research tools, but does not clarify the functions by themselves.

The inventors of the present invention overcame these difficulties and disclosed specific physiological function of GPR35.

5

Brief Disclosure of the Invention

The present invention encompasses the following non-limiting aspects.

One aspect of the present invention is:

a method of screening for a compound that modulates a GPR35 protein, comprising the step of

- 10 (a) contacting a GPR35 protein or a partial polypeptide thereof with a test compound.

The GPR35 protein or the partial polypeptide thereof used in the screening method of the present invention can exist in cells or a membrane fraction.

The screening method of the present invention can be used to screen compounds that modulates neural activity and/or digestive system.

- 15 In the screening method of the present invention, test compound can consist of a plurality of compounds. In this case, what is determined is whether these compounds can, as a combination, modulate a GPR35 protein.

In the screening method of the present invention, a GPR protein or a partial polypeptide thereof of the following can be used:

- 20 (a) a polypeptide having the amino acid sequence of sequence ID. 2, 4, or 6,
(b) a polypeptide having the same amino acid sequence as the polypeptide of (a) except that one or more amino acids are deleted, substituted, or added,
(c) a polypeptide having an amino acid sequence that has at least 80% identity to the the polypeptide of (a),
25 (d) a polypeptide having an amino acid sequence that has at least 90% identity to the the polypeptide of (a),
(e) a polypeptide having an amino acid sequence that has at least 98% identity to the the polypeptide of (a), and
(f) a human GPR35 protein, a mouse GPR35 protein, or a rat GPR35 protein.

- 30 Another aspect of the present invention is:

a method of screening for a compound that inhibits the binding of a ligand to a GPR35 protein, comprising the steps of:

- (a) contacting a GPR35 protein or a partial polypeptide thereof with the ligand,
- (b) contacting a GPR35 protein or a partial polypeptide thereof prepared in the substantially same manner as the one used in the step (a) with the ligand prepared in the substantially same manner as the one used in the step (a), in the presence of a test compound, and
- (c) comparing the results of the step (a) and the step (b) to determine whether the binding of the ligand is affected by the presence of the test compound.

In this screening method of the binding assay, a detectable label can be bound to the ligand, and the step (c) can comprise the step of comparing the detected amount of label in the step (a) and the detected amount of label in the step (b).

In this screening method of the binding assay, the ligand can be selected from zaprinast, an analogue thereof, or a mimetic thereof.

Another aspect of the present invention is a screening method for agonists or antagonists of a GPR35 protein by functional assay.

In the screening method for agonists or antagonists of a GPR35 protein by functional assay, the functional response to be observed can be, for example, the increase of intracellular calcium concentration.

One aspect of agonist screening by functional assay is:

a method of screening for a compound that is an agonist of a GPR35 protein, comprising the steps of:

- (a) adding a test compound to cells expressing a GPR35 protein or a partial polypeptide thereof or to a membrane fraction from the cells, and
- (b) determining whether a functional response is observed.

One aspect of antagonist screening by functional assay is:

a method of screening for a compound that is an antagonist of GPR35 protein, comprising the steps of:

- (a) adding an agonist to cells expressing GPR35 protein or a partial polypeptide thereof or to a membrane fraction from the cells,
- (b) adding an agonist prepared in the substantially same manner as the one used in the step

(a) and a test compound to the cells or the membrane prepared in the substantially same manner as the one used in the step (a), and

(c) comparing a functional response in the step (a) and one in the step (b) to determine whether the functional response is reduced by the test compound.

5 In this screening method of the binding assay, the agonist can be selected from zaprinast, an analogue thereof, or a mimetic thereof.

Another aspect of the present invention is use of zaprinast, an analogue thereof, or a mimetic thereof as a modulator of a GPR35 protein.

10 Another aspect of the present invention is an isolated and/or purified polypeptide of one of the following,

(a) a polypeptide having the amino acid sequence of sequence ID. 2,

(b) a polypeptide having the same amino acid sequence and the same kind of activity as the polypeptide of (a) except that one or more amino acids are deleted, substituted, or added,

15 (c) a polypeptide having an amino acid sequence that has at least 86% identity to the polypeptide of (a),

(d) a polypeptide having an amino acid sequence that has at least 90% identity to the polypeptide of (a), and

(e) a polypeptide having an amino acid sequence that has at least 98% identity to the polypeptide of (a).

20 Another aspect of the present invention is a transformed cells that express the above mentioned polypeptide and an antibody immunospecific for the above mentioned polypeptide.

Another aspect of the present invention is an isolated and/or purified polynucleotide that encodes the above mentioned polypeptide.

25 Another aspect of the present invention is a an isolated and/or purified polynucleotide of one of the following,

(a) a polynucleotide having the nucleotide sequence of sequence ID. 1,

(b) a polynucleotide that is capable of hybridizing under stringent conditions to a polynucleodide having a nucleotide sequence complementary to the nucleotide sequence of

30 the polynucleotide of (a) and that encodes a polypeptide having the same kind of activity as

the polypeptide encoded by the polynucleotide of (a),

(c) a polynucleotide having a nucleotide sequence that has at least 90% identity to the polynucleotide of (a),

(d) a polynucleotide having a nucleotide sequence that has at least 95% identity to the polynucleotide of (a),

(e) a polynucleotide having a nucleotide sequence that has at least 98% identity to the polynucleotide of (a), and

(f) a polynucleotide that encodes any of polypeptides (A) - (E) below;

(A) a polypeptide having the amino acid sequence of sequence ID. 2,

(B) a polypeptide having the same amino acid sequence and the same kind of activity as the polypeptide of (A) except that one or more amino acids are deleted, substituted, or added,

(C) a polypeptide having an amino acid sequence that has at least 86% identity to the polypeptide of (A),

(D) a polypeptide having an amino acid sequence that has at least 90% identity to the polypeptide of (A), and

(E) a polypeptide having an amino acid sequence that has at least 98% identity to the polypeptide of (A).

Another aspect of the present invention is an expression vector containing the above mentioned polynucleotide.

Another aspect of the present invention is transformed cells that stably express any of following polypeptides;

(a) a polypeptide having the amino acid sequence of sequence ID. 2, 4, or 6,

(b) a polypeptide having the same amino acid sequence and the same kind of activity as the polypeptide of (a) except that one or more amino acids are deleted, substituted, or added,

(c) a polypeptide having an amino acid sequence that has at least 80% identity to the polypeptide of (a),

(d) a polypeptide having an amino acid sequence that has at least 90% identity to the polypeptide of (a), and

(e) a polypeptide having an amino acid sequence that has at least 98% identity to the polypeptide of (a).

Another aspect of the present is a novel compounds that can be identified by any of the above mentioned screening method.

Another aspect of the present is a medicament for use to modulate GPR35 activity comprising a compound that can be identified by any of the above mentioned screening method. Non-limiting examples of the modulation of GPR35 activity include modulation of neural activity and modulation of digestive system. In particular, such a compound can be selected from the group consisting of the following compounds;

2-methyl-5-phenyl-pyrazolo[1,5-a]pyrimidin-7(4H)-one,
 3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxy-benzenep
 10 ropanoic acid,
 3-[3-(4,5-dihydro-3-methyl-4-oxo-1-propyl-1H-pyrazolo[3,4-d]pyrimidin-6-yl)-4-propoxypheny
 l]-2-propenoic acid,
 2,4-dihydro-2-methyl-5-[2-(2-methylpropoxy)-5-(1H-tetrazol-5-yl)-3-pyridinyl]-3-propyl-7H-P
 yrazolo[4,3-d]pyrimidin-7-one,
 15 2,4-dihydro-2-methyl-5-[2-(2-methylpropoxy)-5-(1H-1,2,3-triazol-4-yl)-3-pyridinyl]-3-propyl-7
 H-Pyrazolo[4,3-d]pyrimidin-7-one,
 5-(2-ethoxyphenyl)-1,4-dihydro-7H-1,2,3-Triazolo[4,5-d]pyrimidin-7-one,
 3-(4,7-dihydro-7-oxo-1H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl)-4-propoxy-benzenesulfonyl
 chloride,
 20 3-(4,7-dihydro-7-oxo-1H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl)-4-propoxy-benzenesulfonamide,
 5-Nitro-2-(3-phenylpropylamino)benzoic acid,
 2-Cyano-4-hydroxyindole,
 2-(2-Propoxyphenyl)-8-trifluoromethylpurin-6-one, and
 6-phenyl-1-(phenylmethyl)-1H-Bis[1,2,3]triazolo[1,5-a:4',5'-e]pyrimidin-4(5H)-one.

25 Another aspect of the present invention is use of a compound that is identifiable by any of the above mentioned screening method to modulate GPR35 activity. Non-limiting examples of the modulation of GPR35 activity include modulation of neural activity and modulation of digestive system.

Another aspect of the present invention is a method of modulating GPR35 activity
 30 by administering a compound that can be identified by any of the above mentioned screening

method. Non-limiting examples of the modulation of GPR35 activity include modulation of neural activity and modulation of digestive system.

Definitions

5 The terms "homologue" as used herein with regard to polypeptide refers to a polypeptide having a certain homology with a reference polypeptide. Such a homologue can have a homology of preferably, 80% or 85%, more preferably, 90% or 95%, even more preferably 98%. Such a homologue includes a polypeptide having otherwise the same amino acid sequence as a reference polypeptide except that one or more (preferably, several)
10 amino acids are added/substituted/deleted. Such a homologue includes a fragment of a polypeptide.

 The terms "homologue" as used herein with regard to polynucleotides refers to a polynucleotide having a certain homology with a reference polynucleotide. Such a homologue can have a homology of preferably, 80% or 85%, more preferably, 90% or 95%,
15 even more preferably 98%. Such a homologue includes a polynucleotide that encodes a homologue of a polypeptide that a reference polynucleotide encodes. Such a homologue also includes a polypeptide that is complementary to a polynucleotide capable of hybridizing under stringent conditions (e.g. 65°C and 0.1×SSC {1×SSC=0.15M NaCl, 0.015M Na₃ citrate pH7.0}) to a reference polynucleotide. Such a homologue also includes a polynucleotide fragment or
20 partial polypeptide.

 Such sequence homology (identity) can be easily assessed by publicly or commercially available bioinformatics software, such as Blast2 (Altschul, S.F. et al (1997) Nucl. Acids Res. 25, 3389-3402), or programs included in the GCG software package (Devereux et al (1984) Nucl. Acids Res. 12, 387; Wisconsin Package Version 10, Genetics
25 Computer Group (GCG, Madison, Wisconsin), such as Bestfit or Gap.

 The term "analogue" as used herein relates to any substance which is similar in structure to a reference agent (e.g. Zaprinst). As used herein, the term "mimetic" relates to any substance which has the same kind of activity or effect as a reference agent (e.g. Zaprinst).

30 The term "modulator of a receptor" as used herein refers to any substance which

has an direct or indirect effect on the receptor. The term "agonist of a receptor" refers to a substance which can stimulate the receptor. The term "antagonist of a receptor" refers to a substance which can inhibit the stimulation of the receptor by an agonist.

5 The term "functional response" as used herein refers to the reaction that, for example, stimulation of a receptor leads to in cells. In the case of G-protein coupled receptors, this can include, for example, a change in the concentration of cyclic AMP, a transient rise in intracellular calcium concentration, or an opening of an ion channel.

The term "compound" as used herein refers to any chemical entity, including but not limited to a small organic molecule, a peptide, a protein, a modified protein such as a glycoprotein or a lipoprotein, antibodies or fragments thereof, a nucleic acid such as DNA or
10 RNA or modified nucleic acids, such as oligonucleotides with a modified backbone.

The term "isolated and/or purified" polynucleotide/polypeptide as used herein refers to any polynucleotide/polypeptide that is not in a natural condition. Therefore, "isolated and/or purified" polynucleotide includes the case in which only a promoter or an
15 enhancer of an endogenous polynucleotide is modified keeping the polynucleotide intact.

Sequence Listing

Sequence IDs. 1 and 2 respectively show a cDNA nucleotide sequence and an amino acid sequence of rat GPR35.

20 Sequence IDs. 3 and 4 respectively show a cDNA nucleotide sequence and an amino acid sequence of human GPR35.

Sequence IDs. 5 and 6 respectively show a cDNA nucleotide sequence and an amino acid sequence of rat GPR35.

Sequence IDs. 7-23 show nucleotide sequences of primers used in examples.
25

DETAILED DESCRIPTION OF THE INVENTION

The present invention is described in further detail below.

Screening method

30 Generally, the screening method of the present invention is;

a method of screening for a compound that modulates a GPR35 protein, comprising the step of

(a) contacting a GPR35 protein or a partial polypeptide thereof with a test compound.

The screening method can be, but is not limited to, a screening method by binding assay or functional assay. Typical but non-limiting example of a modulating compound is an agonist or an antagonist.

The GPR35 protein or the partial polypeptide thereof used in the screening method of the present invention can exist in cells or a membrane fraction. Thus, a sample of GPR35 may comprise (1) transformed cells prepared as described below, or (2) cells naturally expressing GPR35, or (3) membrane preparations prepared from any cells expressing GPR35, or (4) GPR35 protein enriched or purified from such cells or membranes. The skilled person will be well aware of methods that can be used to enrich or purify GPR35, which include affinity chromatography, size exclusion chromatography, ion exchange chromatography and other methods suitable for the separation of protein from complex mixtures.

Test compounds that are employed in the screening method of the present invention include, for example, peptides, proteins, non-peptide compounds, synthetic compounds, microbial fermentation products, marine organism extracts, plant extracts, cell extracts, and animal tissue extracts. These test compounds may be either novel or known.

Compounds that may be used for screening include, but are not limited to, peptides such as, for example, soluble peptides, including but not limited to members of random peptide libraries; (see, e.g., Lam et al. (1991) Nature 354, 82-84; Houghten et al. (1991) Nature 354, 84-86), and combinatorial chemistry-derived molecular library made of D- and/or L-configuration amino acids, phosphopeptides (including, but not limited to, members of random or partially degenerate, directed phosphopeptide libraries; see, e.g., Songyang et al. (1993) Cell 72, 767-778), antibodies (including, but not limited to, polyclonal, monoclonal, humanized, anti-idiotypic, chimeric or single chain antibodies, and Fab, F(ab')₂ and Fab expression library fragments, and epitope-binding fragments thereof), and small organic or inorganic molecules.

Peptide libraries may be used as a source of test compounds that can be used to

screen in the methods of the invention. Diversity libraries, such as random or combinatorial peptide or nonpeptide libraries can be screened for molecules that specifically bind to a GPR35 protein. Many libraries are known in the art that can be used, e.g., chemically synthesized libraries, recombinant (e.g. phage display libraries), and *in vitro* translation-based libraries.

- 5 Examples of chemically synthesized libraries are described in Fodor et al. (1991) Science 251, 767-773; Houghten et al. (1991), Nature 354, 84-86; Lam et al. (1991), Nature 354, 82-84; Medynski (1994) Bio/Technology 12, 709-710; Gallop et al. (1994), J. Medicinal Chemistry 37, 1233-1251; Ohlmeyer et al. (1993), Proc. Natl. Acad. Sci. USA 90, 10922-10926; Erb et al. (1994), Proc. Natl. Acad. Sci. USA 91, 11422-11426; Houghten et al. (1992)
- 10 Biotechniques 13, 412; Jayawickreme et al. (1994), Proc. Natl. Acad. Sci. USA 91, 1614-1618; Salmon et al. (1993) Proc. Natl. Acad. Sci. USA 90, 11708-11712; PCT Publication No. WO 93/20242; and Brenner and Lerner (1992) Proc. Natl. Acad. Sci. USA 89, 5381-5383.

- Examples of phage display libraries are described in Scott & Smith (1990) Science 249:386-390; Devlin et al. (1990) Science 249, 404-406; Christian, et al. (1992), J. Mol. Biol.
- 15 227, 711-718; Lenstra (1992) J. Immunol. Meth. 152, 149-157; Kay et al. (1993) Gene 128, 59-65; and PCT Publication No. WO 94/18318 dated August 18, 1994.

- By way of example of nonpeptide libraries, a benzodiazepine library (see e.g. Bunin et al. (1994), Proc. Natl. Acad. Sci. USA 91, 4708-4712) can be adapted for use. Peptoid libraries (Simon et al. (1992) Proc. Natl. Acad. Sci. USA 89, 9367-9371) can also be used.
- 20 Another example of a library that can be used, in which the amide functionalities in peptides have been permethylated to generate a chemically transformed combinatorial library, is described by Ostresh et al. (1994) Proc. Natl. Acad. Sci. USA 91, 11138-11142).

- Screening the libraries can be accomplished by any of a variety of commonly known methods. See, e.g., the following references, which disclose screening of peptide
- 25 libraries: Parmley & Smith (1989) Adv. Exp. Med. Biol. 251, 215-218; Scott & Smith (1990) Science 249, 386-390; Fowlkes et al. (1992) BioTechniques 13, 422-427; Oldenburg et al. (1992) Proc. Natl. Acad. Sci. USA 89, 5393-5397; Yu et al. (1994) Cell 76, 933-945; Staudt et al. (1988) Science 241, 577-580; Bock et al. (1992) Nature 355, 564-566; Tuerk et al. (1992) Proc. Natl. Acad. Sci. USA 89, 6988-6992; Ellington et al. (1992) Nature 355, 850-852; U.S. Patent
- 30 No. 5,096,815, U.S. Patent No. 5,223,409, and U.S. Patent No. 5,198,346, all to Ladner et al.;

Rebar & Pabo (1993) Science 263, 671-673; and PCT Publication No. WO 94/18318.

Compounds that can be tested and identified using the methods described herein can include, but are not limited to, compounds obtained from any commercial source, including Aldrich (1001 West St. Paul Ave., Milwaukee, WI 53233), Sigma Chemical (P.O. Box 14508, St. Louis, MO 63178), Fluka Chemie AG (Industriestrasse 25, CH- 9471 Buchs, Switzerland (Fluka Chemical Corp. 980 South 2nd Street, Ronkonkoma, NY 11779)), Eastman Chemical Company, Fine Chemicals (P.O Box 431, Kingsport, TN 37662), Boehringer Mannheim GmbH (Sandhofer Strasse 116, D-68298 Mannheim), Takasago (4 Volvo Drive, Rockleigh, NJ 07647), SST Corporation (635 Brighton Road, Clifton, NJ 07012), Ferro (111 West Irene Road, Zachary, LA 70791), Riedel- deHaen Aktiengesellschaft (P.O. Box D-30918, Seelze, Germany), PPG Industries Inc., Fine Chemicals (One PPG Place, 34th Floor, Pittsburgh, PA 15272). Further any kind of natural products may be screened using the methods of the invention, including microbial, fungal, plant or animal extracts.

Furthermore, diversity libraries of test compounds, including small molecule test compounds, may be utilized. For example, libraries may be commercially obtained from Specs and BioSpecs B.V. (Rijswijk, The Netherlands), Chembridge Corporation (San Diego, CA), Contract Service Company (Dolgoprudny, Moscow Region, Russia), Comgenex USA Inc. (Princeton, NJ), Maybridge Chemicals Ltd. (Cornwall PL34 OHW, United Kingdom), and Asinex (Moscow, Russia).

Still furthermore, combinatorial library methods known in the art, can be utilized, including, but not limited to: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the "one-bead one-compound" library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam (1997) Anticancer Drug Des.12, 145). Combinatorial libraries of test compounds, including small molecule test compounds, can be utilized, and may, for example, be generated as disclosed in Eichler & Houghten (1995) Mol. Med. Today 1, 174-180; Dolle (1997) Mol. Divers. 2, 223-236; and Lam (1997) Anticancer Drug Des. 12, 145-167.

Examples of methods for the synthesis of molecular libraries can be found in the

art, for example in: DeWitt et al. (1993) Proc. Natl. Acad. Sci. USA 90, 6909; Erb et al. (1994) Proc. Natl. Acad. Sci. USA 91, 11422; Zuckermann et al. (1994) J. Med. Chem. 37, 2678; Cho et al. (1993) Science 261, 1303; Carrell et al. (1994) Angew. Chem. Int. Ed. Engl. 33, 2059; Carrell et al. (1994) Angew. Chem. Int. Ed. Engl. 33, 2061; and Gallop et al. (1994) J. Med. Chem. 37, 1233.

Libraries of compounds may be presented in solution (e.g. Houghten (1992) Bio/Techniques 13, 412-421), or on beads (Lam (1991) Nature 354:82-84), chips (Fodor (1993) Nature 364, 555-556), bacteria (U.S. Patent No. 5,223,409), spores (Patent Nos. US 5,571,698; US 5,403,484; and US 5,223,409), plasmids (Cull et al. (1992) Proc. Natl. Acad. Sci. USA 89, 1865-1869) or phage (Scott and Smith (1990) Science 249, 386-390; Devlin (1990) Science 249, 404-406; Cwirla et al. (1990) Proc. Natl. Acad. Sci. USA 87, 6378-6382; and Felici (1991) J. Mol. Biol. 222, 301-310).

Screening the libraries can be accomplished by any of a variety of commonly known methods. See for example the following references, which disclose screening of peptide libraries: Parmley & Smith (1989) Adv. Exp. Med. Biol. 251, 215-218; Scott & Smith (1990) Science 249, 386-390; Fowlkes et al. (1992) BioTechniques 13, 422-427; Oldenburg et al. (1992) Proc. Natl. Acad. Sci. USA 89, 5393-5397; Yu et al. (1994) Cell 76, 933-945; Staudt et al. (1988) Science 241, 577-580; Bock et al. (1992) Nature 355, 564-566; Tuerk et al. (1992) Proc. Natl. Acad. Sci. USA 89, 6988-6992; Ellington et al. (1992) Nature 355, 850-852; U.S. Patent No. 5,096,815, U.S. Patent No. 5,223,409, and U.S. Patent No. 5,198,346, all to Ladner et al., Rebar & Pabo (1993) Science 263, 671-673; and PCT Publication No. WO 94/18318.

Another aspect of the present invention is:

a method of screening for a compound that inhibits the binding of a ligand to a GPR35 protein, comprising the steps of

- (a) contacting a GPR35 protein or a partial polypeptide thereof with the ligand,
- (b) contacting a GPR35 protein or a partial polypeptide thereof prepared in the substantially same manner as the one used in the step (a) with the ligand prepared in the substantially same manner as the one used in the step (a), in the presence of a test compound, and
- (c) comparing the results of the step (a) and the step (b) to determine whether the binding of the ligand is affected by the presence of the test compound.

In this screening method of the binding assay, a detectable label can be bound to the ligand, and the step (c) can comprise the step of comparing the detected amount of label in the step (a) and the detected amount of label in the step (b). For example, ligands labeled with ^{125}I , ^{35}S , ^3H , ^{14}C , ligands labeled with fluorescent compounds such as fluorescein, or
5 ligands labeled with enzymes such as horseradish peroxidase can be used as a labeled ligand. Alternatively, these labeled ligands can be prepared according to per-se known methods.

Another aspect of the screening method of the present invention is a screening method for agonists or antagonists of GPR35 by functional assay.

One aspect of the agonist screening of the present invention is:

10 a method of screening for a compound that is an agonist of a GPR35 protein, comprising the steps of:

- (a) adding a test compound to cells expressing a GPR35 protein or a partial polypeptide thereof or to a membrane fraction from the cells, and
- (b) determining whether a functional response is observed.

15 One aspect of the antagonist screening of the present invention is:

a method of screening for a compound that is an antagonist of GPR35 protein, comprising the steps of:

- (a) adding an agonist to cells expressing GPR35 protein or a partial polypeptide thereof or to a membrane fraction from the cells,
- 20 (b) adding an agonist prepared in the substantially same manner as the one used in the step (a) and a test compound to the cells or the membrane prepared in the substantially same manner as the one used in the step (a), and
- (c) comparing a functional response in the step (a) and one in the step (b) to determining whether the functional response is reduced by the test compound.

25 With regard to the agonist/antagonist screening method described above, in a preferred aspect of the invention, the functional response can be a transient rise in intracellular calcium concentration, measured by using fluorescent dyes such as Fluo-3 or Indo-1 or by other means known to the person skilled in the art; in another preferred aspect of the invention, the functional response is an increase in the rate of respiration of the cells as
30 measured by an increase in the rate of acidification of the medium surrounding the cells as

measured by microphysiometry. In yet another preferred aspect of the invention, the functional response is an increase or decrease in the cyclic AMP concentration or increase in the calcium concentration in the cells, as measured e.g. by increased activity of a reporter gene product wherein the coding region of the reporter gene is functionally linked to a promoter comprising at least one cyclic AMP response element or one element that can respond to the signal transmission that is associated with the increase of the intracellular calcium concentration. Other methods to measure changes in cyclic AMP concentration or calcium concentration in cells are well known to the person skilled in the art. In a further preferred aspect of the invention, cells are transfected with a plasmid or plasmids leading to co-expression of GPR35 and GFP- β -arrestin complex, and an agonist of the receptor is identified by observing clustering of fluorescence, i.e. GFP- β -arrestin complex, on the cell surface. Suitable cells expressing GPR35 can be, for example, selected from cells naturally expressing GPR35, cells where the expression of GPR35 has been upregulated, or cells that has been transfected to express GPR35.

Transfection

The transfectants of the present invention can be prepared by the following non-limiting methods.

A cDNA or genomic DNA that encodes the GPR35 protein can be used to construct an expression vector that comprises a DNA encoding the GPR 35 protein. A DNA that encodes a partial polypeptide having the substantially same kind of ligand-binding activity as the GPR35 protein can also be used. A cDNA or genomic DNA that encodes a known or novel GPR35 protein can be used as well as a synthetic DNA. Specifically, for example, a DNA that encodes the GPR35 protein having the amino acid sequence represented by SEQ ID No. 2, 4, or 6 can be used. An example of such a DNA is a DNA having a base sequence represented by SEQ ID No.1, 3, or 5. These DNAs can also be prepared by known gene engineering techniques.

As an expression vector, for example, pcDNA3.1, pAKKO-111, pAKKO-111H, pXT1, pRC/CMV, pRC/RSV, etc. can be used. As a promoter, any one which functions efficiently in a host cell can be used, for example, SV40 promoter, CMV promoter, HSV-TK

promoter, SR α promoter, RSV promoter, etc. can be used. In addition, it is preferable to use the expression vector further containing an enhancer, splicing signal, poly A addition signal, selective marker, etc. The selective marker includes dihydrofolate reductase genes, neomycin resistance genes (G418 resistance), and the like.

5 The preferred expression vector holding a DNA encoding the GPR35 protein of the present invention is a vector that is inserted with an above-mentioned promoters (in particular, SR α promoter, CMV promoter, RSV promoter, etc.) upstream of the DNA encoding the GPR35 protein, a poly A addition signal downstream of the DNA, a selective marker such as neomycin resistance gene or DHFR gene downstream of the poly A addition
10 signal, and an ampicillin resistance gene downstream of the selective marker. More specifically, an expression vector that comprises a CMV promoter upstream of a DNA that encodes human, rat or mouse GPR35 protein, a poly A addition signal downstream of the DNA, a neomycin resistance gene downstream of the poly A addition signal, and an ampicillin resistance gene downstream of the selective marker is preferable. By the
15 introduction of thus obtained expression vector holding a DNA encoding the GPR35 protein to a host cell, a cell that highly expresses the GPR35 can be obtained.

As to host cells, human embryonic kidney 293 (HEK293) cells (Exp Physiol, 75(3): 309-319 (1990)) and CHO cells (J. Exp. Med., 108: 945 (1995)) are preferred. The HEK293 cells and CHO cells can not only highly express the GPR35 protein but also remarkably
20 stably express it. Preferable combination of an expression vector and host cells can be optimally chosen. For example, the combination of the expression vector represented by hGPR35/pcDNA3.1 and the CHO cells is preferable. For the introduction of an expression vector to host cells, any known method such as calcium phosphate transfection (Virology, 52: 456-467 (1973)), electroporation (EMBO J., 1: 841-845 (1982)), commercially available
25 transfection reagents (for example, FuGENE6 Transfection Reagent by Roche), and the like can be used.

The cells highly expressing the human GPR35 receptor protein may be prepared by first selecting a transformant from the cells transfected with the above-mentioned expression vector using a selective marker as an indicator, followed by clonal selection.

30 When a neomycin resistant gene is used, the resistant cells may be selected by continuous

incubation with addition of G418 to multiply the transgene in the cells, thereby yielding much more expressing cells.

In the incubation of the cells (host cells and transfected cells (regardless of transient or stable expression)) used in the present invention, 0.5-20% fetal calf serum
5 EMEM, DMEM, RPMI1640, MEM- α , and the like may be used. Particularly, when an expression vector containing a neomycin gene as a selective marker is used, it is preferable to use a DMEM medium containing G418/geneticin/neomycin and fetal calf serum. The preferred pH is at approximately 6 to 8. The incubation is usually carried out at about 30-40 °C for a period of about 15 to 200 hours, if required with aeration, agitation, and
10 exchange of the culture medium.

Despite considerable difficulties, the Inventors finally constructed animal cells that continuously and stably express GPR35 after all their commitment and effort. Such cells are indispensable research tool for high through put and large scale screening (for example, HTS). Preparation of such a transfectant is explained in detail in EXAMPLES.

Antibody

The present invention further provides antibodies immunospecific for the rat GPR35 protein. The antibodies may be obtained by administering the polypeptides or epitope-bearing fragments, analogs or cells to an animal, preferably a non-human animal,
20 according to known techniques. For preparation of monoclonal antibodies, any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler, G. and Milstein, C., Nature (1975) 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozboret al., Immunology Today (1983) 4.72) and the EBV-hybridoma technique (Cole et al., Monoclonal Antibodies and
25 Cancer Therapy 77-96, Alan R. Liss, Inc., 1985). Techniques for the production of single chain antibodies, such as those described in U.S. Pat. No. 4,946,778, can also be adapted to produce single chain antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms, including other mammals, may be used to express humanized antibodies. The above-described antibodies may be employed to isolate or to identify clones expressing
30 the polypeptide or to purify the polypeptides by affinity chromatography. Antibodies

against polypeptides of the present invention may also be employed to treat the diseases, amongst others.

Medical Indication

5 Compounds of the present invention (namely, compounds that modulated GPR35 protein (GPR modulator)) can be used to modulate GPR35 protein and hence modulate neurotransmission in the nervous systems (or spinal cord) so as to treat a variety of neurological disorders (for example, CNS disorders). Non limiting examples of such conditions are pain, anxiety, convulsions, cognition disorders, obesity, schizophrenia,
10 neurodegeneration, depression, attention deficit hyperactivity disorder, mania, memory deficit, eating disorders, Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, drug addiction, bipolar disorders, circadian rhythm disorders, migraine, sexual dysfunctions, sleep disorders and eating disorders, urinary diseases, etc.

 Further, compounds of the present invention (namely, compounds that modulated
15 GPR35 protein (GPR modulator)) can be used to modulate GPR35 protein and hence modulate digestive system so as to treat a variety of disease conditions. Non limiting examples of such conditions that can be treated by the agonism of GPR35 are functional dyspepsia, Irritable Bowel Syndrome (IBS), diarrhea, eating disorders, emesis. Non limiting examples of such conditions that can be treated by the antagonism of GPR35 are
20 gastro-esophageal reflux disease, Barrett's esophagus, esophageal achalasia, functional dyspepsia, gastroparesis, postoperative ileus, Irritable Bowel Syndrome (IBS), constipation, eating disorders, non-cardiac chest pain (NCCP), bronchial asthma (BA), bronchitis, and chronic cough (for BA, bronchitis, and chronic cough, those caused by reflux of stomach content are particularly assumed).

25 Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g. for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50.

30 Compounds that exhibit large therapeutic indices are preferred. While compounds that

exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.

The data obtained from the cell culture assays and animal studies can be used in
5 formulating a range of dosages for use in humans. The dosage of such compounds lies
preferably within a range of circulating concentrations that include the ED 50 with little or no
toxicity. The dosage may vary within this range depending upon the dosage form employed
and the route of administration utilized. For any compound used in the method of the
invention, the therapeutically effective dose can be estimated initially from cell culture assays.
10 A dose may be formulated in animal models to achieve a circulating plasma concentration
range that includes the IC₅₀(i. e. the concentration of the test compound which achieves a
half-maximal inhibition of symptoms) as determined in cell culture. Such information can be
used to more accurately determine useful doses in humans. Levels in plasma may be
measured, for example, by high performance liquid chromatography.

15 Pharmaceutical compositions for use in accordance with the present invention may
be formulated in conventional manner using one or more physiologically acceptable carriers or
excipients.

Thus, the compounds and their physiologically acceptable salts and solvates may
be formulated for administration by inhalation or insufflation (either through the mouth or
20 the nose) or oral, buccal, parenteral or rectal administration.

For oral administration, the pharmaceutical compositions may take the form of, for
example, tablets or capsules prepared by conventional means with pharmaceutically
acceptable excipients such as binding agents (e.g. pregelatinised maize starch,
polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline
25 cellulose or calcium hydrogen phosphate); lubricants (e.g. magnesium stearate, talc or silica);
disintegrants (e.g. potato starch or sodium starch glycolate); or wetting agents (e.g. sodium
lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid
preparations for oral administration may take the form of, for example, solutions, syrups or
suspensions, or they may be presented as a dry product for constitution with water or other
30 suitable vehicle before use. Such liquid preparations may be prepared by conventional means

with pharmaceutically acceptable additives such as suspending agents (e.g. sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g. lecithin or acacia); non-aqueous vehicles (e.g. almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g. methyl or propyl-p- hydroxybenzoates or sorbic acid). The
5 preparations may also contain buffer salts, flavoring, coloring and sweetening agents as appropriate.

Preparations for oral administration may be suitably formulated to give controlled release of the active compound.

For buccal administration the compositions may take the form of tablets or
10 lozenges formulated in conventional manner.

For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g.,
dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or
15 other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of e.g. gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

The compounds may be formulated for parenteral administration by injection, e. g.
20 by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g. in ampules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution
25 with a suitable vehicle, e.g. sterile pyrogen-free water, before use.

The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g. containing conventional suppository bases such as cocoa butter or other glycerides.

In addition to the formulations described previously, the compounds may also be
30 formulated as a depot preparation. Such long acting formulations may be administered by

implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

5 The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack may for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration.

10 **EXAMPLES**

The present invention is explained more specifically by examples below, which do not limit the scope of the invention.

Example 1: Original Cloning of human GPR35

A full-length cDNA of human GPR35 was isolated from human Standard Mixed DRG cDNA library (LIFE TECHNOLOGIES; 11649-019, Lot No: 80160b) based upon the known sequence of human GPR35 protein using very well-known technology. Compared with the published sequence of GPR35 (accession number; AF027957), the clone had three missense mutations (T108M, R174A, and R294S) that seemed to be SNPs (the substitutions were registered in databases independently. See also Nat. Genet., 26:163-175 (2000)). The nucleotide sequence of the clone is shown in sequence ID. 3 and the amino acid sequence of the polypeptide encoded by the clone is shown in sequence ID. 4. This was used as template DNA for following experiments to construct expression vectors for human GPR35.

25 **Example 2: Construction of an Expression Vector of FLAG-tagged human GPR35**

A cDNA of FLAG-tagged human GPR35 was generated by PCR using two primers of sequence ID. 7 and sequence ID. 8. The former primer contains *EcoRI* site and the latter primer *XbaI* site. The PCR was performed using Advantage-HF2 PCR Kit (CLONTECH; K1914-1) with the following program: 94 °C for 4min; 30 cycles of 94 °C for 20 sec, 50 °C for 30 sec, 72 °C for 90sec; 72 °C for 4 min. The PCR product was purified by High

Pure™ PCR Product Purification Kit (Roche 1732 676). The purified PCR product was digested with 20 U of *EcoRI* (NEB; R0101S) and 20 U of *XbaI* (NEB; R0145S) in 1×SuRE Cut Buffer H (Roche) at 37 °C for 2.5 hr. A mammalian expression vector, pcDNA3.1(+) (Invitrogen; V790-20) was also digested in the same manner. The samples were
5 electrophoresed with 1% agarose gel, and desired fragments were gel-purified using DNA PREP (IATRON; AGC-001K). Digested pcDNA3.1(+) was treated with “Alkaline Phosphatase, shrimp” (Roche; 1 758 250) at 37 °C for 1 hr. The enzyme was then inactivated at 65 °C for 15min. The treated pcDNA3.1(+) and human FLAG-GPR35 fragments were ligated using Rapid DNA Ligation Kit (Roche; 1 635 379). Then, One Shot
10 TOP10 Chemically Competent *E. coli* (C4040-03) was transformed using 4 µl of the reaction mixture. About 200 transformants were obtained, and 16 colonies were picked up to check by PCR using universal primers, T7 and BGH reverse. Four clones were checked by DNA sequencing. The DNA sequencing was performed by TOYOBO Gene Analysis using T7 and BGH reverse primer, and the data were analyzed by GENETYX-WIN version 4. Finally,
15 two of the properly constructed clones were obtained and used for further experiments. The plasmid map of this vector is shown in Figure 1.

Example 3: Construction of an Expression Vector of Native human and mouse GPR35

A pcDNA3.1 (+) expression vector containing a cDNA of native (namely,
20 not-tagged) human GPR35 was constructed by the substantially same method as those described above. Primers used for PCR were the primer of sequence ID. 9 (5' primer) and the primer of sequence ID. 8 (3' primer). The former primer contains *EcoRI* site and the latter primer *XbaI* site. The plasmid map of the vector is shown in Figure 2. Similarly, a pcDNA3.1 (+) expression vector containing a cDNA of native mouse GPR35 was constructed.
25 Primers used for PCR were the primer of sequence ID. 10 and the primer of sequence ID. 11. Mouse bone marrow total RNA was used for cloning.

Example 4: Cloning of rat GPR35 and Sequencing thereof

To identify and clone rat GPR35 that has not been published, RT-PCR
30 experiments were performed. To generate first-strand cDNA templates for RT-PCR, 5 µg of

Rat Colon Total RNA (CLONTECH; #64066-1) was reverse-transcribed by SUPERScript Preamplification Systems (GIBCO BRL/Invitrogen) according to the attached protocol. To amplify rat GPR35 by RT-PCR, a 5' primer of Sequence ID. 12 and a 3' primer of Sequence ID. 13 was used. These primers were designed according to nucleotide sequences of mouse GPR35 (accession number; BC027429). Mixtures for PCR were prepared using LA Taq with GC Buffer II (TaKaRa; RR02AG) according to 'general reaction mixture for PCR' described in the attached protocol. PCR was performed under the following condition: 94 °C for 4min; 35 cycles of 94 °C for 20 sec, 50 °C for 30 sec, 72 °C for 1 min; 72 °C for 4 min. After PCR, 10 µl of the samples were separated by electrophoresis. Although non-specific amplifications were also observed, PCR product with expected size was obtained. The fragment with expected size was gel-purified using DNA Prep (IATRON; AGC-001K) and TA-cloned using TOPO TA Cloning Kit (Invitrogen; K4500-01). Plasmids from the several independent clones were purified using QIAprep Spin Miniprep Kit (QIAGEN; #27106), and they were sequenced by TOYOBO Gene Analysis using T7 primer and M13 reverse primer. Determined sequences were analyzed by GENETYX-SV/R version 5.2 (GENETYX) and BLAST Search. The clones (plasmids) contained 921-bp ORF. The nucleotide sequence of the clone is shown in sequence ID. 1 and the amino acid sequence of the polypeptide encoded by the clone is shown in sequence ID. 2. Analysis by BLAST Search revealed that it encodes polypeptide that is most similar to the mouse and human GPR35. Homology of rat GPR35 was 72% to human GPR35 and 85% to mouse GPR35 in amino acid sequence. Homology of rat GPR35 was 78% to human GPR35 and 89% to mouse GPR35 in nucleic acid sequence. Therefore, we concluded that the 921-bp ORF was rat GPR35 gene. To determine error-free rat GPR35 gene, several independent experiments were performed.

25 Example 5: Construction of an Expression Vector of rat GPR35

To prepare insert for mammalian expression vector for rat GPR35, PCR was performed using Advantage HF2 PCR Kit (CLONTECH; K1909-1). TA-cloned error-free rat GPR35 was used as a template for the PCR. Two primers used for the PCR were 5' primer of Sequence ID. 14 and 3' primer of Sequence ID. 15. Conditions for the PCR were as follows: 94 °C for 4 min; 30 cycles of 94 °C for 20 sec, 50 °C for 30 sec, 72 °C for 1 min; 72 °C

for 4 min. The fragments in the PCR products were separated by electrophoresis and extracted by DNA Prep. The gel-purified PCR fragments were digested by 20 U of *EcoRI* and 20 U of *XhoI* in 1×SuRECut Buffer H (Roche), and ligated into *EcoRI-XhoI* sites of pcDNA3.1(+). Several single clones were checked by DNA sequencing (TOYOBO Gene
5 Analysis). For large-scale preparation of the plasmid, EndoFree Plasmid Maxi Kit (QIAGEN; 12362) was used.

Example 6: Transient Transfection

HEK293 cells were maintained in DMEM (Invitrogen; 11965-084) supplemented
10 with 10% FBS and penicillin/streptomycin. Expression vectors of FLAG-tagged human GPR35 (FLAG-hGPR35), native human GPR35, and rat GPR35 were prepared as described above. These expression vectors as well as expression vectors (cloned in pcDNA3 (Invitrogen)) of chimeric G proteins (Gqs5, Gqi5 and Gqo5) and G α 16. were used for transfection of HEK293 cells. Transfection of HEK293 cells was performed using FuGENE
15 6 Transfection Reagent (Roche; 814 443) according to the attached protocol.

Example 7: Stable Transfection

Commercially available CHO-G α 15-NFAT β -lactamase cells were maintained in DMEM (Invitrogen 11995-065) supplemented with 10% FBS (Biowhittaker 14-502F), 0.1
20 mM NEAA (Invitrogen 11140-050), 1.0 mM Na-pyruvate (Invitrogen 11360-070), 25 mM HEPES (Invitrogen 15630-080), 3 μ g/ml blasticidin HCl (Invitrogen R210-01), 100 μ g/ml zeocin (Invitrogen R250-01) and penicillin/streptomycin (Invitrogen 15140-122). About 6 x 10⁵ cells were transfected with 4.5 μ g of human GPR35-expression vector using 15 μ l of Lipofectamine 2000 (Invitrogen 11668-019). One-day after transfection, the cells were
25 harvested and re-suspended in a medium prepared by further supplementing DMEM above with 1mg/ml G418 (Invitrogen 11811-031). The cells were seeded into T75 flask (Corning 430641) at a density of 1 x 10⁶ cells/flask and incubated for 11 days in CO₂ incubator. The stable cells were stimulated with 10 μ M of zaprinast (Sigma Z0878) overnight, and selection of zaprinast-sensitive cells was performed on Fluorescence Activated Cell Sorter
30 (FACSVantage SE; Becton Dickinson). For sorting, a substrate of β -lactamase was

prepared by mixing CCF4 (Invitrogen K1028) with pluronic F127 (Invitrogen K1026), PBS (-) (Invitrogen 14190-144) and probenecid (Sigma P8761) just before use. The response to zaprinast on each sorted cell was confirmed by β -lactamase assay and Ca assay. Thus, stably-expressing human GPR35 cell line was established.

5

Example 8: Intracellular Calcium Mobilization Assay

Two days after transfection, the cells were washed twice with Hanks' Balanced Salt Solution (GIBCO BRL; 14175-095), and loaded with 5 μ M Fura 2-AM (DOJINDO; 343-05401) in Hanks' Balanced Salt Solution containing Pluronic F-127 (0.05 %v/v, SIGMA; P-2443) for 1 hour in CO₂ incubator. After the incubation, the cells were harvested by centrifugation and suspended in Hanks' Balanced Salt Solution (GIBCO BRL; 14025-092) (this solution contains calcium chloride, magnesium chloride, and magnesium sulfate) at a density of 1~3 \times 10⁵ cells/mL. Cell suspension (90 μ l) was dispensed to 96-well plates (COSTER; 3904). Addition of 10 μ l of the test compounds and measurement of intracellular calcium mobilization were performed with FDSS6000 (Hamamatsu Photonics).

15

Example 9: Western Blotting

To confirm expression of FLAG-hGPR35, 1.5 \times 10⁶ cells were dissolved in 150 μ l of Tris-SDS-BME Sample Loading Buffer (Owl; ER33) and analyzed by western blotting analysis. 20 μ l of the samples were loaded to READY GELS J (BIO-RAD; 161J391) and separated by electrophoresis in Tris/Glycine/SDS Buffer (BIO-RAD; 161-0732) at 200 volts for 30 min. Proteins were blotted to PVDF membrane (MLIIPORE; IPVH304FO) at 15 V for 30min, and the blotted membrane was blocked by TBS buffer (150 mM NaCl, 20 mM Tris-HCl; pH7.5) containing 1.2 % bovine albumin (SIGMA; A-7030) for 30min. The membranes were incubated in 1,000-fold diluted ANTI-FLAG M2 Monoclonal Antibody (SIGMA; F-3165) for 1 hour and washed with TTBS buffer (TBS buffer containing 0.1% Tween20) three times. Membranes were incubated in 500-fold diluted anti-mouse IgG-HRP (IMMUNOTECH; 0817) as secondary antibody and washed with TTBS buffer three times. FLAG-GPR35 was visualized by ECL Western blotting detection reagents (Amersham pharmacia biotech; RPN 2209), and the signals were detected by IMAGE READER

25

30

LAS-1000 Pro version 2.0 (FUJI PHOTO FILM).

Example 10: Screening for Agonists for human GPR35

To screen agonists for GPR35, we prepared HEK293 cells transiently co-expressing FLAG-tagged human GPR35 (FLAG-hGPR35), chimeric G proteins (Gqs5, Gqi5 and Gqo5) and a promiscuous G protein (Gα16). After the cells were loaded with Fura 2-AM (calcium indicator), intracellular Ca²⁺ mobilization evoked by addition of 10 μM of compounds was detected with FDSS6000 by the method described above. About 1,000 compounds were screened, and we discovered that zaprinast induced intracellular Ca²⁺ mobilization in the co-transfectant. It had no such effect observed in parental HEK293 cells.

As a result of the screening of various compounds, besides Zaprinast, the following compounds were identified to induce intracellular Ca²⁺ mobilization in the co-transfectant.

Identified compound (reference)	EC50(μM)
2-methyl-5-phenyl-pyrazolo[1,5-a]pyrimidin-7(4H)-one (Journal of Organic Chemistry (1959), 24, 779-86)	2
3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxy-benz enepropanoic acid (Cell Pathways, Inc., USPAT No. 6200980)	~3
3-[3-(4,5-dihydro-3-methyl-4-oxo-1-propyl-1H-pyrazolo[3,4-d]pyrimidin-6-yl)-4-propoxyp heny]-2-propenoic acid (Cell Pathways, Inc., USPAT No. 6200980)	0.80
2,4-dihydro-2-methyl-5-[2-(2-methylpropoxy)-5-(1H-tetrazol-5-yl)-3-pyridinyl]-3-propyl-7 H-Pyrazolo[4,3-d]pyrimidin-7-one (Pfizer Limited, WO 2001027112)	1.6
2,4-dihydro-2-methyl-5-[2-(2-methylpropoxy)-5-(1H-1,2,3-triazol-4-yl)-3-pyridinyl]-3-prop yl-7H-Pyrazolo[4,3-d]pyrimidin-7-one (Pfizer Limited, WO 2001027112)	0.50
5-(2-ethoxyphenyl)-1,4-dihydro-7H-1,2,3-Triazolo[4,5-d]pyrimidin-7-one (May and Baker Ltd., USPAT No. 3987160)	1.4
3-(4,7-dihydro-7-oxo-1H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl)-4-propoxy-benzenesulfonyl chloride (May and Baker Ltd., USPAT No. 3987160)	0.30

3-(4,7-dihydro-7-oxo-1H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl)-4-propoxy-benzenesulfonamide (May and Baker Ltd., USPAT No. 3933822)	0.68
5-Nitro-2-(3-phenylpropylamino)benzoic acid (Hoechst A.-G., USPAT No. 4994493)	2
2-Cyano-4-hydroxyindole (Leland Stanford Junior University, USPAT No. 5229412)	2
2-(2-Propoxyphenyl)-8-trifluoromethylpurin-6-one (Smith Kline and French Laboratories Ltd., USPAT No. 5073559)	0.30
6-phenyl-1-(phenylmethyl)-1H-Bis[1,2,3]triazolo[1,5-a:4',5'-e]pyrimidin-4(5H)-one (MDPI Product List, commercially available MDPI)	0.24

Table 1: identified compounds

To confirm the agonistic activity of zaprinast, we tested dose dependencies of the responses in the co-transfectants by the same method. In the co-transfectant, intracellular Ca^{2+} mobilization was induced by the compound dose-dependently, while HEK293 cells co-expressing only the chimeric G proteins and $\text{G}\alpha_{16}$ (mock) showed no response (Figure 3) to the compounds. The expression of FLAG-hGPR35 in the co-transfectant was confirmed by western blotting (data not shown). We also confirmed the agonism of zaprinast for native hGPR35 (Figure 3).

10

Example 11: Confirmation of the Coupling of GPR35

We also examined which G protein(s) was/were coupled to GPR35 using zaprinast. When FLAG-hGPR35 was co-expressed with Gqi5, Gqo5 (these are commercially available) or $\text{G}\alpha_{16}$ in HEK293 cells, intracellular calcium mobilization was induced by zaprinast (Figure 4). On the other hand, the response was not observed in either co-transfectant of Gqs5 and FLAG-hGPR35 or transfectant of FLAG-hGPR35 alone (Figure 2). The expression of FLAG-hGPR35 in the co-transfectant was confirmed by western blotting (data not shown). These data suggest that human GPR35 couples to $\text{G}\alpha_i$, $\text{G}\alpha_o$, and $\text{G}\alpha_{16}$.

Example 12: Intracellular Calcium Mobilization Assay using rat GPR35

To confirm agonist activity of zaprinast for rat GPR35, HEK293 cells transiently co-expressing rat GPR35 and Gqi5 (chimeric G protein) were prepared, and challenged with

zaprinast by a method described above (Figure 5). Zaprinast showed a moderate agonistic activity for human GPR35 (mean EC50 value = 1136 nM) but showed surprisingly high agonistic activity for rat GPR35 (mean EC50 value = 21 nM). Transfectant expressing Gqi5 alone (mock) did not respond to zaprinast (Figure 5). Transfectant expressing GPR35 alone also did not respond to zaprinast (data not shown).

Example 13: Comparative Experiment to Confirm Mechanism

Zaprinast is a well-known PDE5 inhibitor (BIOORG MED CHEM LETT (1996) 6 (15), 1819-1824 and EUR J PHARMACOL (2001) 411, 1-10). In the experiments above, Zaprinast showed its activity only when a GPR35 protein and an appropriate G protein are co-expressed. Therefore, it is understood that the above activity of Zaprinast is mediated by GPR35. However, just for further clarification, self-developed compound (hereinafter referred to as compound A) that is a strong PDE5 inhibitor (its chemical formula is 3-ethyl-5-{5-[(4-ethylpiperazino)sulphonyl]-2-propoxyphenyl}-2-(2-pyridylmethyl)-6,7-dihydro-2H-pyrazolo[4,3-d]pyrimidin-7-one. IC50 value against PDE5 is 540nM for zaprinast and only 0.8nM for the compound A. Compound A is disclosed in Xenobiotica (2001), 31(8-9), 651-664 and 665-676) was used for the calcium mobilization assay. As a result, the compound A, unlike Zaprinast did not show an agonistic activity (Figure 6). This confirms that Zaprinast showed the activity via GPR35 protein. This was also confirmed by a comparative experiment that compared an activity of Zaprinast and the compound A using spinal cord as described below.

Example 14: Electrophysiological Experiment

Spinal cord preparation

Transversely sliced spinal cord preparation was obtained from an adult rat by a method already described in an article (Nakatsuka, et al. Alteration in synaptic inputs through C-afferent fibers to substantia gelatinosa neurons of rat spinal dorsal horn during postnatal development Neuroscience, 99, 549-556, 2000). Briefly, male adult Sprague-Dawley rats (200-350 g; 7-8 weeks old, SLC) were anesthetized with urethane (1.5 g/kg, i.p.). After laminectomy, lumbosacral spinal cord was removed and transferred into ice

cold Krebs solution (1-3°C) pre-equilibrated with 95% O₂ / 5% CO₂. The composition of the Krebs solution was (in mM): 117 NaCl, 3.6 KCl, 2.5 CaCl₂, 1.2 MgCl₂, 1.2 NaH₂ PO₄, 25 NaHCO₃ and 11 glucose. The pia was removed after cutting all the ventral and dorsal roots near the root entry zone. The spinal cord was mounted on a microslicer (DTK-3000W,
5 Dosaka EM Co. Ltd., Kyoto, Japan) and then a transverse slice (500 µm thick) was cut. The slice was placed on a nylon mesh in the recording chamber of about 0.5 ml volume. The cut slice was continuously superfused at a flow rate of 18-20ml/min with the Krebs solution in 95% O₂ / 5% CO₂, pH 7.2, for pre-incubation (longer than 1hr, 36±1 °C). The institutional animal care and use committee approved the experimental procedure.

10 Patch clamp recordings

Substantia gelatinosa (SG) neurons were identified by their location in the preparation by a method in previously-reported article (Yoshimura and, Nishi Blind patch-clamp recordings from substantia gelatinosa in adult rat spinal cord slices: pharmacological properties of synaptic currents, Neuroscience, 53, 519-526, 1993). Briefly,
15 under a binocular stereomicroscope and with transmitted illumination, the SG neurons were clearly discernable as a translucent band. Blind whole-cell recordings were performed from SG neurons with patch pipettes which had tip resistance of 8-10 MΩ when the pipettes were filled with the solution containing (in mM): 135 K-gluconate, 5 KCl, 2 MgCl₂, 0.5 CaCl₂, 5 EGTA, 5 HEPES, and 5 ATP. Each recording was performed on a cell in a fresh slice
20 without prior application of any drugs, except some experiments. Signals were gained with a patch-clamp amplifier (Axopatch 200B, Axon Instruments). Data were low-pass filtered at 2 kHz, digitized at 333 kHz with an A/D converter, stored and analyzed with a personal computer using the software of pCLAMP (Version 9.0, Axon Instruments), Axograph (Version 4.6.2, Axon Instruments) and Origin (Version 6.1, Microcal). All experiments were
25 performed to isolate excitatory postsynaptic currents (EPSCs) at the holding potential (V_H) of -70 mV, at which GABA and glycine-mediated synaptic currents were negligible. Miniature EPSCs (mEPSCs) were recorded in the presence of 2 µM tetrodotoxin (TTX).

Application of drugs

All tested compounds were applied through the bath solution by exchanging the
30 perfusion solution at a flow rate of 14-18 ml/min. Zaprinast was purchased from Sigma (St.

Louis, MO, USA) and TTX was purchased from WAKO (Japan). The above mentioned self developed compound A was provided by medicinal chemists at Pfizer Sandwich Laboratories.

Data analysis and statistics

Data analyses were performed with the help of detection program of synaptic currents in the Axograph software. The events that posses the shape of a rapid rise followed by a slow decay and the peak exceeded -3 or -4 pA were identified as mEPSCs to be analyzed. Each selected synaptic current was visually inspected to eliminate detection errors. Changes of the inter-event interval and amplitude of mEPSCs were evidenced with the help of cumulative histograms of these parameters, and ascertained with the Kolmogorov-Smirnov test. For this test, $P < 0.01$ was taken to be statistically significant. Data were presented as mean \pm SEM

Result: Effect of zaprinast on mEPSCs

Regarding to the effects of zaprinast on mEPSCs in SG neurons of the spinal cord, zaprinast ($10 \mu\text{M}$) inhibited the frequency of the mEPSCs (Fig. 7). Figs. 7B and 7C demonstrate the effects of zaprinast ($10 \mu\text{M}$) on cumulative distribution of the inter-event interval and the amplitude of the mEPSC. Zaprinast significantly inhibited the frequency ($P < 0.001$) of the mEPSCs (7B), while the amplitude of mEPSCs ($p > 0.01$) was not (7C). The kinetics of mEPSCs was not affected by zaprinast (7D). Of 5 cells examined, 4 cells showed significant suppressions of mEPSC frequency in each cells ($P < 0.01$, KS-test). Membrane current was not induced by zaprinast up to $100 \mu\text{M}$ ($n = 2$, Data not shown). These data suggest that zaprinast inhibited the excitatory transmission presynaptically.

Result: Mechanism of the inhibition of mEPSC frequency by zaprinast

In order to study whether this inhibition of the mEPSC induced by zaprinast was GPR35 agonism or PDE-5 inhibition, we examined the effect of the compound A above, a selective PDE-5 inhibitor, on the mEPSCs. The frequency and amplitude of mEPSCs were not affected by the compound A of its concentration from 20 nM up to $10 \mu\text{M}$ (Fig. 8). Since this no inhibitory effect of the compound A was also confirmed in the SG neurons whose frequency of mEPSCs was reduced by the application of zaprinast of $10 \mu\text{M}$ ($n=2$, Data not shown), the compound A and zaprinast are quite different from their mode of action on mEPSCs. These results indicate that zaprinast would exert its inhibitory effect on mEPSCs

via GPR35 agonism but not PDE5 inhibition.

Result

As described above, it has been demonstrated that electrophysiological evidence that activation of GPR35 produced suppression in the release of excitatory neurotransmitters from the presynaptic terminals of excitatory interneuron. These presynaptic GPR35 may play an important role in the inhibitory controls of nociceptive transmission at the spinal cord level.

Example 15: Tissue Distribution of human GPR35

Total RNA samples used to synthesize templates are listed in Table 2. Reverse transcription was performed using SUPERScript Preamplification Systems (CLONTECH) according to the attached protocol. To amplify transcripts of human GPR35, two nucleotide primers, the primer of Sequence ID. 16 and the primer of Sequence ID 17 were designed. Premix Taq Ex Taq Version (TaKaRa; RR003A) was used for PCR. PCR was performed in a volume of 20 μ l under the following program: 94 °C for 4min; 32 cycles of 94 °C for 20 sec, 65 °C for 30 sec, 72 °C for 60 sec; 72 °C for 4 min. The samples were analyzed by electrophoresis using 1% agarose gel. For a positive control, 1 pg of expression vector of FLAG-tagged GPR35 was used. For an internal control, GAPDH was amplified with the same procedure except for annealing temperature (50 °C), number of cycles (25 cycles) and primers (Sequence IDs 18 and 19). To exclude the possibility of contamination of genomic DNA to the templates, experiments without reverse transcription (in absence of SuperScript II reverse transcriptase) were performed, and no amplifications were observed except for positive control.

Tissue	Maker	Catalogue #	Conc.(μ g/ μ l)
Trachea	CLONTECH	#K4000-1 (Human Panel I)	1.00
Heart	CLONTECH	#K4001-1 (Human Panel II)	1.00
Kidney	GIBCO BRL	11410-016	2.50
Adrenal gland	CLONTECH	64016-1	1.00
Stomach	CLONTECH	#K4000-1 (Human Panel I)	1.00

Small intestine	CLONTECH	#K4001-1 (Human Panel II)	1.00
Colon	CLONTECH	#K4001-1 (Human Panel II)	1.00
Brain	CLONTECH	#K4003-1 (Human Panel IV)	1.00
Cerebellum	CLONTECH	#K4003-1 (Human Panel IV)	1.00
Spinal cord	CLONTECH	#K4003-1 (Human Panel IV)	1.00
Dorsal horn	ABS	custom-made RNA	0.95
DRG	ABS	custom-made RNA	0.76

Table 2. List of total RNA used for RT-PCR.

Tissue distribution of GPR35 in human was determined by RT-PCR (Figure 9). Striking signals of GPR35 were observed in spinal cord (whole), (spinal) dorsal horn, DRG, brain, cerebellum, small intestine and colon. On the other hand, little or no signal was observed in trachea, heart, kidney, adrenal gland, and stomach. The internal control (GAPDH) was amplified equally with each template. Furthermore, it was confirmed that no amplified products were obtained by experiment without the reverse-transcription reaction (data not shown). These data show that GPR35 is mainly expressed in the nervous system, small intestine and colon.

Example 16: Tissue Distribution of rat GPR35

Rat DRG and spinal cord were extracted from a 10-week-old pregnant female Sprague-Dawley rat sacrificed by CO₂ (all animal care and sample collection were approved by the Research Ethics Committee). The tissues were extracted in 1 ml of ISOGEN (Nippon Gene), and total RNAs were purified according to attached protocol. Other total RNAs were purchased from BD Clontech or UNITECH. They are summarized in Table 3.

Tissue	Maker	Catalogue #
Brain	CLONTECH (BD)	64075-1
Cerebellum	UNITECH	203
Cerebrum	UNITECH	202
Skeletal muscle	UNITECH	215

Uterus	UNITECH	213
Heart	UNITECH	205
Lung	UNITECH	206
Liver	UNITECH	208
Bladder	CLONTECH (BD)	64077-1
Stomach	UNITECH	207
Small intestine	UNITECH	211
Colon	CLONTECH (BD)	64066-1
DRG	Prepared in this study	
Spinal cord	Prepared in this study	

Table 3. List of total RNAs of rat used in this study

To generate first-strand cDNA templates for RT-PCR, 5 µg of total RNA (listed in Table 1) was reverse-transcribed by SUPERScript Preamplification Systems (GIBCO BRL/Invitrogen) according to the attached protocol. To exclude the possibility of contamination of genomic DNA to the templates, a series of samples without SuperScript II RT (-RT) were prepared in parallel as negative controls. Twentieth of the each reverse-transcribed sample was used as template for subsequent PCR. To amplify rat GPR35 by RT-PCR, two primers (Sequence Ids 20 and 21) were designed according to nucleotide sequences of rat GPR35. Mixtures for PCR were prepared using LA Taq with GC Buffer (TaKaRa; RR02AG) according to 'general reaction mixture for PCR' described in the attached protocol. PCR for rat GPR35 was performed under the following condition: 94 °C for 4 min; 35 cycles of 94 °C for 20 sec, 58 °C for 30 sec, 72 °C for 1 min; 72 °C for 4 min. For internal controls of reverse transcription, GAPDH was amplified with the same procedure except for cycle number (30 cycles) and primers (Sequence IDs 22 and 23). After PCR, 10 µl of each sample was separated by electrophoresis, and DNAs were visualized by ethidium bromide staining.

To determine tissue distribution of rat GPR35, RT-PCR analysis was performed. Predominant expression in digestive system (colon, small intestine, stomach) and DRG were observed (Figure 10). This result is consistent with a previous study in human GPR35.

Example 17: Ligand Binding Assay

Transiently or stably transfected cells expressing GPR35 are harvested by scraping (24-72 hours after the transfection in the case of transient transfection) and resuspended in 50 ml of ice-cold HEPES buffer (pH7.4) (containing 0.32 M Sucrose, 10mM EDTA, 10mM MgCl₂). The resulting suspension is centrifuged at 48,000 g, 4 °C for 30 minutes. The resulting pellet is resuspended in the same buffer and centrifugation described above is repeated. The resulting pellet (membrane fraction) is suspended in an appropriate volume of an assay buffer and preserved at -80 °C. The protein concentration is determined via Bradford's assay (Biorad), according to the manufacturer's recommendations.

The membrane fraction containing 50 µg protein is then incubated with various potential ligands, radiolabeled to high specific activity, for about 30-120 minutes at room temperature (the optimal conditions, ion concentrations, incubation time and temperature can be determined for each ligand with our undue difficulty according to technical knowledge well known to those skilled in the art). Reaction solution is filtrated by suction filtration using SKATRON cells harvester when the reaction ends. Right after filtration, the filter is washed by the assay buffer three times. Wallac GF/B filter is immersed in 0.3% (v/v) PEI (Polyethyleneimine; Sigma) for 1 hour before use. The GF/B filter is dried after washing and bound radioactivity on Filtermats is determined using a liquid scintillation counter. The specific binding is defined as the difference between total radioactivity bound minus the radioactivity measured in the presence of an excess of unlabelled ligand. Mock-transfected cells are also measured to assess whether the host cells express receptors for the ligands used endogenously.

Example 18: Gastric emptying rate

To evaluate the involvement of GPR35 in gastric emptying rate, male Crj:SD(IGS) rats (Charles River Japan, Inc., 200-270 g) were used after fasted overnight. Drugs were administered to rats as summarized in Table 4 below, and after the administration of the drugs, a semi-solid meal (methylcellulose: 7 g, glucose: 7.5 g, cornstarch: 9 g, casein: 15 g in 275 ml of water; hereinafter "test meal") was given orally by 3 mL/head.

	Drug	Dose (mg/kg)	Number of rats	Time when drug was administered (prior to the administration of test meal)
Experiment 18-1	(Vehicle)	-	7	15 min prior
	Zaprinast	0.01	7	15 min prior
	Zaprinast	0.1	6	15 min prior
	Zaprinast	1	6	15 min prior
	Cisapride	3	7	15 min prior
Experiment 18-2	(Vehicle)	-	6	15 min prior
	Zaprinast	10	5	15 min prior
	Zaprinast	30	5	15 min prior
	Zaprinast	100	5	15 min prior
	Cisapride	3	8	15 min prior
Experiment 18-3	(Vehicle)	-	6	5 min prior
	Compound A	30	6	5 min prior

Table 4. Application of Drug

Thirty minutes after test meal was given, the rats were sacrificed with CO₂. The stomach was removed and weighed ("Weight A"). The stomach was opened and rinsed with saline, and weighed again ("Weight B"). "Weight of the stomach content" was calculated as the difference between them ("Weight A"- "Weight B") "Gastric emptying rate" was calculated by the following formula

"Gastric emptying rate" (%)

$$= 100 \times (\text{"Weight of given test meal"} - \text{"Weight of the stomach content"}) / (\text{Weight of given test meal})$$

Zaprinast was purchased from Sigma (St. Louis, MO, USA). Cisapride, a positive control, and Compound A (see Example 13), a selective PDE5 inhibitor were synthesized at

Pfizer. Drugs were suspended with 0.1% methylcellulose solution and administered orally. In the table above, "Vehicle" means 0.1 % methylcellulose solution. Dose of drugs or vehicle was 5mL/kg for the Experiment 18-1 and 18-2, and 2mL/kg for the Experiment 18-3.

5 Data were presented as mean \pm SEM. The comparison between the control group and the drug-treated group was carried out by Dunnett's test or Student's t-test. P values of less than 0.01 were regarded as significant.

Figure 11 shows the result of Experiment 18-1 and 18-2. Zaprinast, a GPR35 agonist, delayed rat gastric emptying ability in a dose dependent manner when orally administered by 1-100mg/kg. This delaying effect was statistically significant. In the figure,
10 it can be deemed that negative "gastric emptying rate" is due to that gastric emptying ability was inhibited and that gastric juices and the like secreted remained in stomach resulting in stomach content overweighing test meal.

Figure 12 shows the result of Experiment 18-3. This experiment was conducted to observe the effect of PDE 5 inhibitor, compound A on rat gastric emptying ability in order to
15 confirm that rat gastric emptying ability is realized by agonism of GPR35, because Zaprinast is an agonist of GPR35 as well as an antagonist of PDE5. Compound A enhanced rat gastric emptying ability and this enhancement was statistically significant. Therefore, it can be concluded that inhibition of gastric emptying ability caused by Zaprinast is realized by agonism of GPR35.

20 As discussed above, agonism of GPR35 will inhibit rat gastric emptying ability.

CLAIMS

1. A method of screening for a compound that modulates a GPR35 protein, comprising the step of:
 - (a) contacting a GPR35 protein or a partial polypeptide thereof with a test compound.
- 5 2. A method of screening for a compound that modulates neural activity, comprising the steps of:
 - (a) contacting a GPR35 protein or a partial polypeptide thereof with a test compound.
3. A method of screening for a compound that modulates digestive system, comprising the steps of:
 - 10 (a) contacting a GPR35 protein or a partial polypeptide thereof with a test compound.
4. A method of screening for a compound that inhibits the binding of a ligand to a GPR35 protein, comprising the steps of:
 - (a) contacting a GPR35 protein or a partial polypeptide thereof with the ligand,
 - (b) contacting a GPR35 protein or a partial polypeptide thereof prepared in the substantially
15 same manner as the one used in the step (a) with the ligand prepared in the substantially same manner as the one used in the step (a), in the presence of a test compound, and
 - (c) comparing the results of the step (a) and the step (b) to determine whether the binding of the ligand is affected by the presence of the test compound.
5. The method according to claim 4, wherein
20 a detectable label is bound to said ligand, and
said step (c) comprises the step of comparing the detected amount of label in the step (a) and the detected amount of label in the step (b).
6. A method of screening for a compound that is an agonist of a GPR35 protein, comprising the steps of:
 - 25 (a) adding a test compound to cells expressing a GPR35 protein or a partial polypeptide thereof or to a membrane fraction from the cells, and
 - (b) determining whether a functional response is observed.
7. A method of screening for a compound that is an antagonist of GPR35 protein, comprising the steps of:
 - 30 (a) adding an agonist to cells expressing GPR35 protein or a partial polypeptide thereof or to

- a membrane fraction from the cells,
- (b) adding an agonist prepared in the substantially same manner as the one used in the step (a) and a test compound to the cells or the membrane prepared in the substantially same manner as the one used in the step (a), and
- 5 (c) comparing a functional response in the step (a) and one in the step (b) to determine whether the functional response is reduced by the test compound.
8. A method according to claim 6 or 7, wherein said functional response is a transient rise in intracellular calcium concentration.
9. The method according to claim 4 or 7, wherein said ligand or said agonist is selected
- 10 from zaprinast, an analogue thereof, or a mimetic thereof.
10. The method according to any one of claims 1-4, wherein the GPR35 protein or the partial polypeptide thereof in the step (a) exists in cells or a membrane fraction.
11. The method according to any one of claims 1-4, 6, and 7 to screen a compound for use in the treatment or prevention of any of the following conditions:
- 15 pain, anxiety, convulsions, cognition disorders, obesity, schizophrenia, neurodegeneration, depression, attention deficit hyperactivity disorder, mania, memory deficit, eating disorders, Parkinson's disease, Huntington's disease, Alzheimer's disease, amyotrophic lateral sclerosis, drug addiction, bipolar disorders, circadian rhythm disorders, migraine, sexual dysfunctions, sleep disorders, functional dyspepsia, Irritable Bowel Syndrome (IBS), diarrhea, emesis,
- 20 gastro-esophageal reflux disease, Barrett's esophagus, esophageal achalasia, gastroparesis, postoperative ileus, constipation, non-cardiac chest pain (NCCP), bronchial asthma(BA), bronchitis, and chronic cough.
12. The method according to any one of claims 1-4, 6, and 7, wherein said test compound consists of a plurality of compounds.
- 25 13. A method according to any one of claims 1-4, 6, and 7, wherein said GPR35 protein is selected from the following:
- (a) a polypeptide having the amino acid sequence of sequence ID. 2, 4, or 6,
- (b) a polypeptide having the same amino acid sequence as the polypeptide of (a) except that one or more amino acids are deleted, substituted, or added,
- 30 (c) a polypeptide having an amino acid sequence that has at least 80% identity to the the

polypeptide of (a),

(d) a polypeptide having an amino acid sequence that has at least 90% identity to the the polypeptide of (a),

(e) a polypeptide having an amino acid sequence that has at least 98% identity to the the polypeptide of (a), and

(f) a human GPR35 protein, a mouse GPR35 protein, or a rat GPR35 protein.

14. Use of zaprinast, an analogue thereof, or a mimetic thereof as a modulator of a GPR35 protein.

15. An isolated and/or purified polypeptide of one of the following;

(a) a polypeptide having the amino acid sequence of sequence ID. 2,

(b) a polypeptide having the same amino acid sequence and the same kind of activity as the polypeptide of (a) except that one or more amino acids are deleted, substituted, or added,

(c) a polypeptide having an amino acid sequence that has at least 86% identity to the polypeptide of (a),

(d) a polypeptide having an amino acid sequence that has at least 90% identity to the polypeptide of (a), and

(e) a polypeptide having an amino acid sequence that has at least 98% identity to the polypeptide of (a).

16. An isolated and/or purified polynucleotide of one of the following;

(a) a polynucleotide having the nucleotide sequence of sequence ID. 1,

(b) a polynucleotide that is capable of hybridizing under stringent conditions to a polynucleotide having a nucleotide sequence complementary to the nucleotide sequence of the polynucleotide of (a) and that encodes a polypeptide having the same kind of activity as the polypeptide encoded by the polynucleotide of (a),

(c) a polynucleotide having a nucleotide sequence that has at least 90% identity to the polynucleotide of (a),

(d) a polynucleotide having a nucleotide sequence that has at least 95% identity to the polynucleotide of (a),

(e) a polynucleotide having a nucleotide sequence that has at least 98% identity to the polynucleotide of (a), and

- (f) a polynucleotide that encodes the polypeptide according to the claim 15.
17. An expression vector containing the polynucleotide according to claim 16.
18. Transformed cells that express the polypeptide according to claim 15.
19. An antibody immunospecific for the polypeptide according to claim 15.
- 5 20. Transformed cells that stably express any of following polypeptides;
- (a) a polypeptide having the amino acid sequence of sequence ID. 2, 4, or 6,
- (b) a polypeptide having the same amino acid sequence and the same kind of activity as the polypeptide of (a) except that one or more amino acids are deleted, substituted, or added,
- (c) a polypeptide having an amino acid sequence that has at least 80% identity to the
- 10 polypeptide of (a),
- (d) a polypeptide having an amino acid sequence that has at least 90% identity to the polypeptide of (a), and
- (e) a polypeptide having an amino acid sequence that has at least 98% identity to the polypeptide of (a).
- 15 21. A novel compound that is identifiable by the method according to any one of claims 1-4, 6, and 7.
22. A medicament for use to modulate GPR35 activity comprising a compound that is identifiable by the method according to any of claims 1-3, 5, and 6.
23. The medicament according to claim 21 comprising a compound selected from the
- 20 group consisting of the following compounds;
- 2-methyl-5-phenyl-pyrazolo[1,5-a]pyrimidin-7(4H)-one,
- 3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxy-benzenep
- ropanoic acid,
- 3-[3-(4,5-dihydro-3-methyl-4-oxo-1-propyl-1H-pyrazolo[3,4-d]pyrimidin-6-yl)-4-propoxypheny
- 25 l]-2-propenoic acid,
- 2,4-dihydro-2-methyl-5-[2-(2-methylpropoxy)-5-(1H-tetrazol-5-yl)-3-pyridinyl]-3-propyl-7H-P
- yrzolo[4,3-d]pyrimidin-7-one,
- 2,4-dihydro-2-methyl-5-[2-(2-methylpropoxy)-5-(1H-1,2,3-triazol-4-yl)-3-pyridinyl]-3-propyl-7
- H-Pyrazolo[4,3-d]pyrimidin-7-one,
- 30 5-(2-ethoxyphenyl)-1,4-dihydro-7H-1,2,3-Triazolo[4,5-d]pyrimidin-7-one,

3-(4,7-dihydro-7-oxo-1H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl)-4-propoxy-benzenesulfonyl chloride,

3-(4,7-dihydro-7-oxo-1H-1,2,3-triazolo[4,5-d]pyrimidin-5-yl)-4-propoxy-benzenesulfonamide, 5-Nitro-2-(3-phenylpropylamino)benzoic acid,

5 2-Cyano-4-hydroxyindole,

2-(2-Propoxyphenyl)-8-trifluoromethylpurin-6-one, and



6-phenyl-1-(phenylmethyl)-1H-Bis[1,2,3]triazolo[1,5-a:4',5'-e]pyrimidin-4(5H)-one.

24. Use of a compound that is identifiable by the method according to any one of claims 1-4, 6, and 7 to modulate GPR35 activity.


10 25. Use of a compound that is identifiable by the method according to any one of claims 1-4, 6, and 7 for the manufacture of a medicament to modulate GPR35 activity.

26. A method of modulating GPR35 activity by administering a compound that is identifiable by the method according to any one of claims 1-4, 6, and 7.


1/9

FIG. 1**FIG. 2**



2/9

FIG. 3





3/9

FIG. 4




4/9

FIG. 5**FIG. 6**



5/9

FIG. 7A**FIG. 7B****FIG. 7C****FIG. 7D**

6/9

FIG. 8A**FIG. 8B****FIG. 8C**

7/9

FIG. 9**FIG. 10**

8/9




FIG. 11A**FIG. 11B**

FIG. 12

PC32099A_GPR35 SEQUENCE for NY (Identical to PC32099)
SEQUENCE LISTING

<110> Pfizer Inc.; Pfizer Japan Inc. (for Japan)

<120> GPR35

<130> PC32099

<160> 23

<170> PatentIn version 3.1

<210> 1

<211> 921

<212> DNA

<213> rat

<400> 1

```

atgaacaata caaatgttag catctcccg tggcctgcig cagtaacca catcttcacc      60
atctacttgg tcttgcigt ggtcctgggc ctgcctgcca atggcctggc actctgggia    120
ttctgtatc gcataacca gttgacggag acccgagctt aatgaccaa cctggtcttg    180
gtgaagctt gccctcctg ctctctgcca ttctgtctgt actccctgaa atacagtact    240
tcggacacac ccatctgcca gctctcacag ggcatctacc tggtaacag gtaatagaga    300
ataagcttgg taaccgcat tgcctgggac cgtatgttg cagtgggca tccccctgct    360
gccctgagc tgcgttccc acggcaggct ggagcagtg gtgtggcct ctgggtgata    420
ggtgtacct cctgtgtact gctctgggc ctggggalac aggagggtg cttctgtctc    480
agcagccaaa atcgttaca cttcagcacc actgccttct cgtctgtgg attctacctg    540
ccgtctgcca tagtggtct ctctctctt caggttgtga ctgcttggc ccgaaggcca    600
gccactgacg tggagcaggt ggaggccact cagaaggcca cccgatgtt ctgggccaac    660
ttggcctgt ttatcatct cttctgccc ctgcattga tctgacagt gcaggtctcc    720
ctgaacctcc acacctggc tgcctgaaac atcttcagcc gtgcctgac aatcacagcc    780
aagctctcag acatcaacig ctgcttggt gccatctgt actactacat ggccaaagag    840
ttccaggatg cgtcttggc ggccacagcc tctagcacac ccacaagag ccaagatact    900
cagagctga gccacaccia g                                     921

```

<210> 2

<211> 306

<212> PRT

<213> rat

<400> 2

```

Met Asn Asn Thr Asn Cys Ser Ile Leu Pro Trp Pro Ala Ala Val Asn
1           5           10           15

```

```

His Ile Phe Thr Ile Tyr Leu Val Leu Leu Leu Val Leu Gly Leu Leu
20           25           30

```

```

Leu Asn Gly Leu Ala Leu Trp Val Phe Cys Tyr Arg Met His Gln Trp
35           40           45

```

```

Thr Glu Thr Arg Val Tyr Met Thr Asn Leu Ala Val Ala Asp Val Cys
50           55           60

```

```

Leu Leu Cys Ser Leu Pro Phe Val Leu Tyr Ser Leu Lys Tyr Ser Thr

```

<210> 3
<211> 930
<212> DNA
<213> human

<400> 3
atgaatggca cctacaacac ctgtggctcc agcgacctca cctggocccc agcgatcaag 60
ctgggcttct acgcctactt gggcgctctg ctggctctag gcctctgtct caacagcttg 120
ggcctctggg tgttctgtct cgcgatcgag cagtggacgg agaccgcgat ctacatgacc 180

PC32099A_GPR35 SEQUENCE for NY (Identical to PC32099)

```

aacctggcggg tggccgacct ctgctgtgtg tgcaccttgc ccttcgtgtc gcactccctg 240
cgagacacct cagacacgcc gctgtgccag ctctccagg gcatctacct gaccaacagg 300
tacaigagca tcagccctgt catggccatc gccgtggacc gctatgtgga cgtgcggcac 360
ccgtgtgtgt cccgggggct ggggtccccc aggoaggtgt cggcgtgtgt cgcgggtctc 420
tgggtgtgtg tcatggcttc cctgtgtgtc cgtgtgtctc tggggattca ggaggcgggc 480
ttctgtctca ggagcaaccg gcacaatttc aactccatgg cgttcccgct gctgggattc 540
taactgcccc tggccgtgtt ggtcttctgc tccctgaagg tggtagctgc cctggcccag 600
aggccaccca ccgacgtggg gcaggcagag gccaccgcca aggcgtcccg catgtctgg 660
gccaaccttc tgggttctgt ggtctgtctc ctgccccgtc acgtggggct gacagtgcgc 720
ctgcagttgg gctggaacgc ctgtgccttc ctggagacga tccgtcgcgc cctgtacata 780
accagcaagc tctcagatgc caactgtctc ctggagccca tctctacta ctacatggcc 840
aaggagtccc agggaggctc tgcactggcc gtggctccca gtgctaaggc ccacaaaagc 900
caggactctc tgtcgtgac cctgcctaa 930

```

<210> 4
 <211> 309
 <212> PRT
 <213> human

<400> 4

Met Asn Gly Thr Tyr Asn Thr Cys Gly Ser Ser Asp Leu Thr Trp Pro
 1 5 10 15

Pro Ala Ile Lys Leu Gly Phe Tyr Ala Tyr Leu Gly Val Leu Leu Val
 20 25 30

Leu Gly Leu Leu Leu Asn Ser Leu Ala Leu Trp Val Phe Cys Cys Arg
 35 40 45

Met Gln Gln Trp Thr Glu Thr Arg Ile Tyr Met Thr Asn Leu Ala Val
 50 55 60

Ala Asp Leu Cys Leu Leu Cys Thr Leu Pro Phe Val Leu His Ser Leu
 65 70 75 80

Arg Asp Thr Ser Asp Thr Pro Leu Cys Gln Leu Ser Gln Gly Ile Tyr
 85 90 95

Leu Thr Asn Arg Tyr Met Ser Ile Ser Leu Val Met Ala Ile Ala Val
 100 105 110

Asp Arg Tyr Val Ala Val Arg His Pro Leu Arg Ala Arg Gly Leu Arg
 115 120 125

Ser Pro Arg Gln Ala Ala Val Cys Ala Val Leu Trp Val Leu Val
 130 135 140

Ile Gly Ser Leu Val Ala Arg Trp Leu Leu Gly Ile Gln Glu Gly Gly
 145 150 155 160

Phe Cys Phe Arg Ser Thr Arg His Asn Phe Asn Ser Met Ala Phe Pro

PC32099A_GPR35 SEQUENCE for NY (Identical to PC32099)

165

170

175

Leu Leu Gly Phe Tyr Leu Pro Leu Ala Val Val Val Phe Cys Ser Leu
180 185 190

Lys Val Val Thr Ala Leu Ala Gln Arg Pro Pro Thr Asp Val Gly Gln
195 200 205

Ala Glu Ala Thr Arg Lys Ala Ala Arg Met Val Trp Ala Asn Leu Leu
210 215 220

Val Phe Val Val Cys Phe Leu Pro Leu His Val Gly Leu Thr Val Arg
225 230 235 240

Leu Ala Val Gly Trp Asn Ala Cys Ala Leu Leu Glu Thr Ile Arg Arg
245 250 255

Ala Leu Tyr Ile Thr Ser Lys Leu Ser Asp Ala Asn Cys Cys Leu Asp
260 265 270

Ala Ile Cys Tyr Tyr Tyr Met Ala Lys Glu Phe Gln Glu Ala Ser Ala
275 280 285

Leu Ala Val Ala Pro Ser Ala Lys Ala His Lys Ser Gln Asp Ser Leu
290 295 300

Cys Val Thr Leu Ala
305

<210> 5
<211> 924
<212> DNA
<213> mouse

<400> 5
atgaatagta caacctgtaa cagcaccctc acgiggcctg ctcccgicaa caactcttc 60
atcatctact cagccttgcg getgggtgcg ggcctgcgc tcaacagcgt ggcactcgg 120
gtattcgcg atgcctgca ccagtgaca gagaccgca tctatatgac caacctggct 180
gtggccgacc tctgcctgc ctgcctctg ccatttgcg tctactccct gaaatatagt 240
tcttcagaca caccctcgc ccagctctca cagggcctct acctggocaa cagatacatg 300
agcataagcc tggcactgc catgtcgtg gaccgctatg tggcagtcg gcatccctg 360
cgtgcgcgtg agctgcggc cccgagacag gctgcagcag tctgtgtggo ccttgggtg 420
atagtggtca cctccctggt agtgcgtgg cgcctgggga tgcaggaggg tggcttctg 480
ttcagcagcc aaaccggcg caatttcage accactgcct tctactgct gggattctac 540
ctgcgcctgg ccactgtgt ctctgcctt ttgcaggtag tgcctgtct atcgagaagg 600
ccagccgtg atgtgggga ggcagaggcc acccnaaagg ccaccacat ggtctgggco 660
aacttggctg tcttgcct ctctctctg ccttgcctg tggctctgac cgtgcaggc 720
tccctgaacc tcaatctcgt tctgcctga gacacttca ggcgtgcct gtccataca 780
ggtaaactct cagacacna ctgtgcctg gatgcctct gtactacta catggccaga 840
gattccagg aagcttcaa gccagccag tcttccaaca caccacaca gaccnaagat 900

PC32099A_GPR35 SEQUENCE for NY (Identical to PC32099)
 tcccagatcc tgagccctcac ctag 924

<210> 6
 <211> 307
 <212> PRT
 <213> mouse

<400> 6

Met Asn Ser Thr Thr Cys Asn Ser Thr Leu Thr Trp Pro Ala Ser Val
 1 5 10 15

Asn Asn Phe Phe Ile Ile Tyr Ser Ala Leu Leu Leu Val Leu Gly Leu
 20 25 30

Leu Leu Asn Ser Val Ala Leu Trp Val Phe Cys Tyr Arg Met His Gln
 35 40 45

Trp Thr Glu Thr Arg Ile Tyr Met Thr Asn Leu Ala Val Ala Asp Leu
 50 55 60

Cys Leu Leu Cys Ser Leu Pro Phe Val Leu Tyr Ser Leu Lys Tyr Ser
 65 70 75 80

Ser Ser Asp Thr Pro Val Cys Gln Leu Ser Gln Gly Ile Tyr Leu Ala
 85 90 95

Asn Arg Tyr Met Ser Ile Ser Leu Val Thr Ala Ile Ala Val Asp Arg
 100 105 110

Tyr Val Ala Val Arg His Pro Leu Arg Ala Arg Glu Leu Arg Ser Pro
 115 120 125

Arg Gln Ala Ala Ala Val Cys Val Ala Leu Trp Val Ile Val Val Thr
 130 135 140

Ser Leu Val Val Arg Trp Arg Leu Gly Met Gln Glu Gly Gly Phe Cys
 145 150 155 160

Phe Ser Ser Gln Thr Arg Arg Asn Phe Ser Thr Thr Ala Phe Ser Leu
 165 170 175

Leu Gly Phe Tyr Leu Pro Leu Ala Ile Val Val Phe Cys Ser Leu Gln
 180 185 190

Val Val Thr Val Leu Ser Arg Arg Pro Ala Ala Asp Val Gly Gln Ala
 195 200 205

Glu Ala Thr Gln Lys Ala Thr His Met Val Trp Ala Asn Leu Ala Val
 210 215 220

Phe Val Ile Cys Phe Leu Pro Leu His Val Val Leu Thr Val Gln Val
 225 230 235 240

Ser Leu Asn Leu Asn Thr Cys Ala Ala Arg Asp Thr Phe Ser Arg Ala
 245 250 255

Leu Ser Ile Thr Gly Lys Leu Ser Asp Thr Asn Cys Cys Leu Asp Ala

PC32099A_GPR35 SEQUENCE for NY (Identical to PC32099)

260

265

270

Ile Cys Tyr Tyr Tyr Met Ala Arg Glu Phe Gln Glu Ala Ser Lys Pro
 275 280 285

Ala Thr Ser Ser Asn Thr Pro His Lys Ser Gln Asp Ser Gln Ile Leu
 290 295 300

Ser Leu Thr
 305

<210> 7
 <211> 61
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> primer

<400> 7
 ccggaatcgc ccacatgga ttacaaggat gacgacgata agaattggcac ctacaacacc 60
 t 61

<210> 8
 <211> 30
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> primer

<400> 8
 tcgtctagaa ttaggcgagg gtcacgcaca 30

<210> 9
 <211> 36
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> primer

<400> 9
 ccggaatcgc ccacatgaa tggcacctac aacacc 36

<210> 10
 <211> 40
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> primer

<400> 10
 ccccgaaatc gccacatga atagiacaac ctgtaacagc 40

<210> 11
 <211> 34
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> primer

<400> 11
 cccctcagc ctaggtgagg ctacagatct ggga 34

PC32099A_GPR35 SEQUENCE for NY (Identical to PC32099)

<210> 12
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> primer

<400> 12
 tccgtcagat gagccctagg acc 23

<210> 13
 <211> 26
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> primer

<400> 13
 cacaggttcc tctggccctt ggcatg 26

<210> 14
 <211> 36
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> primer

<400> 14
 ccccgaaatc gccaccaiga acaatacaaa ttgtag 36

<210> 15
 <211> 30
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> primer

<400> 15
 cccctctcag ctaggtgagg ctccagctct 30

<210> 16
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> primer

<400> 16
 cactccctgc gagacacctc agaca 25

<210> 17
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> primer

<400> 17
 tagtagcaga tggcgiccag gcagc 25

<210> 18

PC32099A_GPR35 SEQUENCE for NY (Identical to PC32099)

<211> 17
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> primer

 <400> 18
 tgcaccacca acigctt 17

 <210> 19
 <211> 17
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> primer

 <400> 19
 tactccttgg aggccat 17

 <210> 20
 <211> 24
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> primer

 <400> 20
 aaattgtagc atcctcccgt ggcc 24

 <210> 21
 <211> 24
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> primer

 <400> 21
 tatcttggct ctgtggggt gtgc 24

 <210> 22
 <211> 24
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> primer

 <400> 22
 gtcttcacca ccatggagaa ggc 24

 <210> 23
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> primer

 <400> 23
 gtgatggcat ggactgtgt catga 25

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
15 September 2005 (15.09.2005)

PCT

(10) International Publication Number
WO 2005/085867 A3

(51) International Patent Classification:

C07K 14/72 (2006.01) **A61K 31/00** (2006.01)
G01N 33/68 (2006.01) **A61K 39/00** (2006.01)

Chita-gun, Aichi-ken 479-2393 (JP). **KOMADA, Tohru** [JP/JP]; Pfizer Global Research and Development, 2, Aza 5-gochi, Taketoyo-cho, Chita-gun, Aichi-ken 470-2393 (JP).

(21) International Application Number:

PCT/IB2005/000382

(74) Agents: **FULLER, F., Grover, Jr.** et al; Pfizer Inc., 201 Tabor Road, Morris Plains, NJ 07950 (US).

(22) International Filing Date:

14 February 2005 (14.02.2005)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/548,719 27 February 2004 (27.02.2004) US

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

(71) Applicant (for JP only): **PFIZER JAPAN, INC.** [JP/JP]; Shinjuku Bunka Quint Bldg., 3-22-7, Yoyogi, Shibuya-ku, Tokyo 151-8589 (JP).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for all designated States except JP, US): **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, NY 10017 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **TANIGUCHI, Yasuhiro** [JP/JP]; Pfizer Global Research and Development, 2, Aza 5-gochi, Taketoyo-cho, Chita-gun, Aichi-ken 470-2393 (JP). **KACHI, Hiroko** [JP/JP]; Pfizer Global Research and Development, 2, Aza 5-gochi, Taketoyo-cho, Chita-gun, Aichi-ken 470-2393 (JP). **TOMOTOSHI, Kimihiko** [JP/JP]; Pfizer Global Research and Development, 2, Aza 5-gochi, Taketoyo-cho, Chita-gun, Aichi-ken 470-2393 (JP). **SHINJO, Katsuhiko** [JP/JP]; Pfizer Global Research and Development, 2, Aza 5-gochi, Taketoyo-cho,

Published:

— with international search report

(88) Date of publication of the international search report:

20 April 2006

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SCREENING METHOD FOR EMULATORS OF NEUTRAL ACTIVITY AND DIGESTIVE SYSTEM USING GPR35

(57) Abstract: The present invention primarily relates to function analysis of GPR35, an orphan GPCR (G protein coupled receptor), a screening method to identify modulators (agonists/antagonists) of the receptor, cells stably expressing the receptor, and the discovery of modulators of the receptor. The present invention also relates to novel rat GPR35.



WO 2005/085867 A3

INTERNATIONAL SEARCH REPORT

International Application No
PCT/IB2005/000382

A. CLASSIFICATION OF SUBJECT MATTER CG7K14/72 GO1N33/68 A61K31/00 A61K39/00				
According to International Patent Classification (IPC) or to both national classification and IPC				
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) C07K GO1N A61K				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched				
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal , Sequence Search, WPI Data, BIOSIS, EMBASE				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No		
X	WO 99/64452 A (SMITHKLINE BEECHAM CORPORATION) 16 December 1999 (1999-12-16) page 3, lines 10-24; claims 1,4,6-12; example 8	1-8, 10-13, 15-22, 24-26		
Y	WO 00/08155 A (INCYTE PHARMACEUTICALS, INC; HILLMAN, JENNIFER, L; YUE, HENRY; UL, PR) 17 February 2000 (2000-02-17) page 6, line 26 - page 7, line 17 page 8, lines 24-29 page 9, line 32 - page 10, line 1 page 16, lines 8-11 page 26, lines 30-33; claims 1,12-20 page 29, lines 21-28; claims 1,12-20 ----- -/--	1-8, 10-13, 15-22, 24-26		
<div style="display: flex; justify-content: space-between;"> <input checked="" type="checkbox"/> Further documents are listed in the continuation of box C <input checked="" type="checkbox"/> Patent family members are listed in annex </div>				
* Special categories of cited documents				
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; vertical-align: top; border: none;"> "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed </td> <td style="width: 50%; vertical-align: top; border: none;"> "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family </td> </tr> </table>			"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family
"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family			
Date of the actual completion of the international search <div style="text-align: center; font-weight: bold;">7 July 2005</div>		Date of mailing of the international search report <div style="text-align: center; font-weight: bold;">29. 11. 2005</div>		
Name and mailing address of the ISA European Patent Office, P B 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel (+31-70) 340-2040, Tx 31 651 epo nl, Fax (+31-70) 340-3016		Authorized officer <div style="text-align: center; font-weight: bold;">Boi angi u, C</div>		

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB2005/000382

-C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>wo 02/Q59344 A (MERCK & CO., INC; LIU, QINGYUN; CLEMENTS, MICHELLE; MCDONALD, TERRENCE) 1 August 2002 (2002-08-01)</p> <p>page 1, lines 22-26 page 72, lines 10-16 page 86; example 9 claims 1,14,18,21,24,25,27-37</p> <p>-----</p>	<p>1-8, 10-13, 15-22, 24-26</p>
X	<p>DATABASE Geneseq [Online] 11 April 2000 (2000-04-11), "Human G-protein coupled receptor GPR35A." XP002330409 retrieved from EBI accession no. GSP:AA58645 Database accession no. AAY58645 the whole document</p> <p>-----</p>	<p>1,2, 4-13, 15-20, 24-26</p>
Y	<p>DATABASE Geneseq [Online] 31 May 2000 (2000-05-31), "Human receptor-associated protein from Incyte clone 3083742." XP002330411 retrieved from EBI accession no. GSP:AA69989 Database accession no. AAY69989 the whole document</p> <p>-----</p>	<p>1-8, 10-13, 15-22, 24-26</p>
Y	<p>DATABASE Geneseq [Online] 4 March 2003 (2003-03-04), "Human G protein-coupled receptor GPR35 protein SEQ ID NO:492." XP002330412 retrieved from EBI accession no. GSP:ABP82002 Database accession no. ABP82002 the whole document</p> <p>-----</p>	<p>11,13, 15-20</p>
Y	<p>DATABASE Uni Prot [Online] 16 October 2001 (2001-10-16), "Probable G-protein coupled receptor 35." XP002330587 retrieved from EBI accession no. UNIPROT:GPR35_MOUSE Database accession no. GPR35_MOUSE the whole document</p> <p>-----</p>	<p>11,13, 15-20</p>
	-/-	

INTERNATIONAL SEARCH REPORT

International Application No
PCT/IB2005/000382

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>DATABASE UniProt [Online] 1 March 2003 (2003-03-01), "Mus musculus adult male bone cDNA, RIKEN full-length enriched library, clone:9830121M19 product :G protein-coupled receptor 35, full insert sequence." XP002330588 retrieved from EBI accession no. UNIPROT:Q8CB97 Database accession no. Q8CB97 the whole document</p> <p>-----</p>	13,15-20
Y	<p>DATABASE EMBL [Online] 21 November 2002 (2002-11-21), "Rattus norvegicus clone CH230-unknown, *** SEQUENCING IN PROGRESS ***, 9 unordered pieces." XP002330589 retrieved from EBI accession no. EM_HTG:AC1372 Database accession no. AC137209 the whole document</p> <p>-----</p>	13,15-20
P,X	<p>WO 2004/040000 A (PRIMAL, INC; GAITANARIS, GEORGE, A; BERGMANN, JOHN, E; GRAGEROV, ALEXA) 13 May 2004 (2004-05-13)</p> <p>page 2, lines 5-13 page 4, lines 16-24 page 130, lines 1-3 page 285, line 29 - page 286, line 5 page 287, lines 5-11 page 292, lines 10-28 page 297, lines 28-30 claim 151; table 2</p> <p>-----</p>	1-8, 10-13, 15-22, 24-26
P,X	<p>DATABASE Geneseq [Online] 29 July 2004 (2004-07-29), "Mouse GPCR GPR35, SEQ ID NO: 497." XP00330410 retrieved from EBI accession no. GSP:AD029395 Database accession no. AD029395 the whole document</p> <p>-----</p>	1-8, 10-13, 15-22, 24-26
A	<p>US 6 403 305 B1 (GERSHENGORN MARVIN C ET AL) 11 June 2002 (2002-06-11)</p> <p>column 1, line 54 - column 3, line 8 column 8, line 61 - column 9, line 4 column 12, line 51 - line 57 claims 1,11,12,15-17</p> <p>-----</p>	1-8, 10-13, 15-22, 24-26

-/--

INTERNATIONAL SEARCH REPORT

International Application No
PCT/IB2005/000382

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
A	<p>WO 02/061087 A (LIFESPAN BIOSCIENCES, INC; BURMER, GLENNA, C; ROUSH, CHRISTINE, L; BRO) 8 August 2002 (2002-08-08)</p> <p>abstract; figure 1 -----</p>	<p>1-8, 10-13, 15-22, 24-26</p>

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/IB2005/000382

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9964452	A	16-12-1999	EP 1084142 A1	21-03-2001
			JP 2002517222 T	18-06-2002
WO 0008155	A	17-02-2000	NONE	
WO 02059344	A	01-08-2002	CA 2431522 A1	01-08-2002
			EP 1363655 A2	26-11-2003
			US 2005075494 A1	07-04-2005
WO 2004040000	A	13-05-2004	AU 2003300776 A1	25-05-2004
			CA 2498264 A1	13-05-2004
			EP 1581648 A2	05-10-2005
us 6403305	B1	11-06-2002	AU 6149898 A	26-08-1998
			EP 1015478 A1	05-07-2000
			WO 9834948 A1	13-08-1998
WO 02061087	A	08-08-2002	US 2003113798 A1	19-06-2003

INTERNATIONAL SEARCH REPORT

International application No

PCT/IB2 005/000382

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.b of the first sheet)

1 With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, the international search was carried out on the basis of

a type of material

☒

a sequence listing

☐

table(s) related to the sequence listing

b format of material

☒

in written format

☒

in computer readable form

c time of filing/furnishing

☒

contained in the international application as filed

☒

filed together with the international application in computer readable form

☐

furnished subsequently to this Authority for the purpose of search

2 ☐ In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished

3 Additional comments

INTERNATIONAL SEARCH REPORT

International application No
PCT/IB2005/000382**Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons

- 1 ☒ Claims Nos 14,21-26
because they relate to subject matter not required to be searched by this Authority, namely
Although claims 24-26 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
- 2 ☐ Claims Nos
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically
- 3 ☒ Claims Nos
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows

see additional sheet

- 1 ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims
- 2 ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee
- 3 ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid. Specifically claims Nos
- 4 ☒ No required additional search fees were timely paid by the applicant. Consequently this International Search Report is restricted to the invention first mentioned in the claims. It is covered by claims Nos
1-13, 15-20

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest
- ☐ No protest accompanied the payment of additional search fees

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-13,15-20

method of screening for a compound that modulates GPR35 protein

2. claims: 14,21-26 (partially)

zaprinast and derivatives thereof as:

a medicament comprising a compound selected from the group consisting of the following compounds;
 5-(2-ethoxy phenyl)-1,4-dihydro-7H-1,2,3-Triazol o[4,5-d] pyrimidin-7-one,
 3-(4,7-dihydro-7-oxo-1H-1,2,3-triazol o[4,5-d]pyrimidin-5-yl)-4-propoxy-benzenesulfonyl chloride,
 3-(4,7-dihydro-7-oxo-1H-1,2,3-triazol o[4,5-d]pyrimidin-5-yl)-4-propoxy-benzenesulfonamide,
 6-phenyl -1-(phenylmethyl)-1H-bis[1, 2,3] triazol o[1,5-a:4',5'-el]pyrimidin-4(5H)-one
 and use thereof to modulate GPR35 protein

3. claim: 23 (partially)

a medicament comprising a compound selected from the group consisting of the following compounds;
 2-methyl -5-phenyl -pyrazol o[1,5-a] pyrimidin-7 (4H)-one,
 3-(4,7-dihydro-1-methyl -7-oxo-3-propyl -1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxy-benzenepropanoic acid,
 3-[3'-(4,5-dihydro-methyl -4-oxo-1-propyl -1H-pyrazol o[3,4-d] pyrimidin-6-yl)-4-propoxyphenyl]-2-propenoic acid,
 2,4-dihydro-2-methyl -5-[2-(2-methyl propoxy) -5-(1H-tetrazol -5-yl)-3-pyridinyl]-3-propyl -7H-pyrazol o[4,3-d] pyrimidin-7-one
 2,4-dihydro-2-methyl -5-[2-(2-methyl propoxy) -5-(1H-1,2,3-triazol -4-yl)-3-pyridinyl]-3-propyl -7H-pyrazol o[4,3-d] pyrimidin-7-on

4. claim: 23 (partially)

a medicament comprising;
 5-Nitro-2-(3-phenyl propyl amino) benzoic acid

5. claim: 23 (partially)

a medicament comprising;
 2-Cyano-4-hydroxyindole

6. claim: 23 (partially)

FURTHER INFORMATION CONTINUED FROM POT/ISA/ 210

a medicament comprising;
2- (2-Propoxyphenyl)-8-trifluoromethyl purine-6-one
